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Joydeep Ghosh 
ROLE OF S6K1 IN REGULATING SELF-RENEWAL OF  
HEMATOPOIETIC STEM CELLS AND PROPAGATION OF LEUKEMIA 
The development and function of hematopoietic stem cells (HSCs) is regulated 
by numerous signaling pathways including Akt-mechanistic target of rapamycin 
complex1 (mTORC1) pathway. Dysregulation of this pathway results in impaired 
HSC function and contributes to the development of hematologic malignancies. 
Activated mTORC1 phosphorylates and subsequently activates ribosomal protein 
S6 kinase 1 (S6K1). To study the role of S6K1 in hematopoiesis as well as 
leukemogenesis, we used a genetic model of S6K1 deficient mice (S6K1-/-). We 
found that loss of S6K1 expression in HSCs results in reduction of absolute HSC 
number in bone marrow (BM). Following chemotherapy, cycling HSCs undergo 
apoptosis and quiescent HSCs are required to cycle to regenerate the 
hematopoietic system. S6K1 regulates the quiescence of HSCs and in the 
absence of S6K1, mice are more susceptible to repeated myeloablative stress. 
We also observed that loss of expression as well as gain of expression of S6K1 
affects the self-renewal ability of HSCs. Interestingly, when we overexpressed 
S6K1, it also resulted in reduced self-renewal of HSCs. Next, we assessed the 
role of S6K1 in the propagation of acute myeloid leukemia (AML). The mixed-
lineage leukemia (MLL) gene is required for the maintenance of adult HSCs. 
Translocations in MLL are detected in approximately 5-10% of adult acute 
leukemia patients and in approximately 70% of acute leukemias in infants. We  
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expressed MLL-AF9 fusion oncoprotein in WT and S6K1-/- hematopoietic stem 
and progenitor cells (HSC/Ps) and performed serial transplantation. Upon 
secondary transplantation, recipients of S6K1 deficient AML cells survived 
significantly longer compared to controls. In vitro, pharmacological inhibition of 
S6K1 activity resulted in reduced growth of primary human cells expressing MLL-
AF9. Both human and murine HSC/Ps expressing MLL-AF9 showed reduced 
mTORC1 activity upon inhibition of S6K1 suggesting that loss of S6K1 activity 
results in reduced Akt-mTORC1 activation both upstream and downstream of 
mTORC1. Overall, our studies establish a critical role of S6K1 activity in the 
maintenance of HSC function and in the propagation of leukemia. 
 Reuben Kapur, Ph.D., Chairman 
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Chapter 1: Introduction 
The production of blood cells is a continuous process and is maintained 
throughout one’s lifetime. It has been estimated that a man weighing 70 kgs may 
produce 1 trillion blood cells every single day, which include 200 billion red blood 
cells (RBC) and 70 billion neutrophilic leukocytes (Dancey et al., 1976; Ogawa, 
1993). This continuous production of blood cells has been termed hematopoiesis, 
which derives from the Greek words haima (blood) and poiein (to make). The 
hematopoietic system has been considered the model paradigm to study the 
properties and functions of stem cells as well as understanding their contribution 
to diseases. The hematopoietic system is composed of a vast network of cells 
that are part of a definitive functional hierarchy. The hematopoietic cells 
contribute to different physiological processes as well as protect our body by 
mounting immune responses against different pathogens. To maintain 
hematopoiesis throughout lifetime, the hematopoietic stem cells (HSC) have to 
undergo self-renewal, differentiation and proliferation. These processes are 
regulated by a host of signaling networks and deregulation of these networks 
results in hematologic malignancies including acute myeloid leukemia (AML). 
Among different cellular signaling pathways, mechanistic target of rapamycin 
complex 1 (mTORC1) pathway has been identified as a critical regulator of HSC 
development and function. The focus of this chapter is to give a brief overview of 
development and function HSCs as well as to define the components of the 
mTORC1 pathway. 
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Hematopoietic stem cells: 
  In the early 20th century, the diversity in morphology of different 
hematopoietic cells at different states of differentiation was described. To 
account for this diversity, Maximow hypothesized that hematopoiesis is 
organized as a cellular hierarchy that originates from a common precursor, a 
hematopoietic stem cell (HSC) (Maximow, 1902). Later, the existence of HSCs 
was further established when transplantation of cells derived from bone marrow 
(BM) or spleen from non-irradiated donors rescued hematopoietic system of 
irradiated recipients (Jacobson et al., 1950a; Jacobson et al., 1950b; Lorenz et 
al., 1951). Studies by Till and McCulloch demonstrated that the regenerative 
potential of HSCs can be assayed using in vivo repopulation assays (Becker et 
al., 1963; Till and McCulloch, 1961). These studies revealed the existence of 
single clonogenic cells within the hematopoietic system. BM hematopoietic cells, 
upon transplantation, could create macroscopic colonies in spleens of lethally 
irradiated recipients in proportion to the number of cells transplanted (Becker et 
al., 1963; Siminovitch et al., 1963; Till and McCulloch, 1961; Wu et al., 1968). 
These data led to the hypothesis that the colony forming units-spleen (CFU-S) 
were derived from a single hematopoietic cell. These findings were followed by 
development of clonal in vitro assays, which along with immunophenotypic 
characterization of cell surface markers of different hematopoietic populations 
have resulted in establishment of a defined hematopoietic hierarchy. Multipotent 
HSCs are at the top of this hierarchy while terminally differentiated cells are at 
the bottom. The studies by Till and McCulloch also demonstrated the importance 
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of mouse as a model system to study hematopoiesis. Since then, assays based 
on mouse models have been indispensable to study both steady-state 
hematopoiesis as well as malignant hematopoiesis. Genetic approaches using 
mouse models involving loss or gain of gene functions in HSCs and 
hematopoietic progenitor cells (HPCs) have helped to identify genes involved in 
regulating the development and functions of HSCs (Rossi et al., 2012). 
Immunophenotypic characterization of HPCs and HSCs: 
HSCs and HPCs can be identified based on the presence or absence of 
certain markers on the cell surface of mouse BM hematopoietic cells. Initially, BM 
hematopoietic cells with long-term repopulating ability were identified by the 
absence of markers specific for mature lineage cells (Lin-), low expression level 
of Thy1.1 and expression of stem cell antigen-1 (Sca1) on the cell surface. The 
lineage markers that were accounted for were B220 (B cells), Gr1 (granulocytes), 
Mac1 (myelomonocytic cells), CD4 and CD8 (T cells) (Spangrude et al., 1988). 
Transplantation of 40 Thy1loLin-Sca1+ cells was sufficient to obtain donor-derived 
engraftment in irradiated hosts. Moreover, the donor cells were able to 
differentiate into myeloid and lymphoid cells in recipient hosts (Spangrude et al., 
1988). Next, c-Kit was identified as another marker to identify HSCs. Okada et al. 
rescued hematopoiesis in lethally irradiated mice by transplanting Lin-Sca1+c-Kit+ 
(LSK) cells (Okada et al., 1992). Later, Osawa et al. demonstrated that a single 
LSK cell expressing low or no CD34 (CD34lo/-) can reconstitute the hematopoietic 
system of 21% of recipients (Osawa et al., 1996). Another cell surface marker 
that has been used to identify HSCs is fms-related tyrosine kinase-3 (Flt3). 
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Upregulation of Flt3 expression in HSCs was associated with reduced self-
renewal ability (Adolfsson et al., 2001). Based on CD34 and Flt3 expression level 
and repopulating ability, CD34-Flt3-LSK cells were defined as long-term HSCs 
(LT-HSC) whereas short-term HSCs (ST-HSC) were CD34+Flt3-LSK cells and 
multi-potent progenitors (MPP) were CD34+Flt3+LSK cells (Yang et al., 2005). 
Signaling lymphocyte activation molecule (SLAM) family of receptors, 
CD150, CD48 and CD244, along with LSK markers (SLAM-LSK) are another set 
of markers that have been used to identify HSCs. Initially, based on SLAM 
markers, HSCs and HPCs have been subdivided into three distinct populations: 
CD150+CD244−CD48− (HSC), CD244+CD150−CD48- (MPP) and most restricted 
progenitors CD48+CD244+CD150− (Kiel et al., 2005; Yilmaz et al., 2006a). Based 
on the expression level of CD229, the SLAM-LSK cells were further subdivided 
into the following populations: CD150+CD48-/lowCD229-/lowCD244-LSK (HSC-1), 
CD150+CD48-/lowCD229+CD244-LSK (HSC-2), CD150-CD48-/lowCD229-/low 
CD244-LSK (MPP-1), CD150-CD48-/lowCD229+CD244-LSK (MPP-2), CD150- 
CD48-/lowCD229+CD244+LSK (MPP-3), CD150-CD48+LSK (HPC-1), and 
CD150+CD48+LSK (HPC-2) (Oguro et al., 2013). When HSC-1 and HSC-2 
populations were transplanted into lethally irradiated mice, HSC-1 cells showed 
increased long-term repopulating activity suggesting that HSC-1 cells have 
maximum HSC activity (Oguro et al., 2013).  
Downstream of HSCs, the lineage restricted progenitor cells lack self-
renewal ability. The lineage restricted progenitors can be subdivided into 
following populations: common myeloid progenitor (CMP), granulocyte-monocyte 
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progenitor (GMP), megakaryocyte-erythrocyte progenitor (MEP), and common 
lymphoid progenitors (CLP) (Akashi et al., 2000) (Figure 1). Akashi et al. have 
demonstrated that there are three important critical decision points in 
hematopoietic hierarchy: (i) LT-HSCs lose their self-renewal ability and undergo 
transition to ST-HSC, (ii) HSCs differentiate to either myeloid lineage (by 
generating CMP) or lymphoid lineage (by generating CLP), and (iii) the decision 
of CMPs to differentiate into either the granulocyte/macrophage lineage (by 
generating GMPs) or the megakaryocyte/erythrocyte lineage (by generating 
MEPs) (Akashi et al., 2000). From their model and other studies, it has been 
established that HSCs differentiate into MPPs, which do not possess self-
renewal potential, but can differentiate into oligopotent progenitors, namely CLP 
and CMP (Akashi et al., 2000; Nakorn et al., 2003; Pronk et al., 2007). CMPs 
give rise to GMP and MEPs that in turn differentiate into lineage committed 
myeloid effector cells, whereas CLPs generate lymphoid cells. 
Although the hematopoietic hierarchy in mouse has been well defined, 
recent studies have revealed the existence of HSCs with lineage bias. Following 
transplantation, HSCs display skewed myeloid to lymphoid ratios that has given 
rise to the hypothesis that HSCs have a bias to commit to a particular lineage 
(Muller-Sieburg et al., 2004). Myeloid biased HSCs are able to self-renew 
following serial transplantation. However, their differentiation into lymphoid cells 
is diminished (Muller-Sieburg et al., 2004). Challen et al., on the basis of CD150 
and Hoechst dye efflux based side population (SP) cells, showed that there is a 
bias amongst HSCs to differentiate into distinct lineages (Challen et al., 2010). 
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Figure 1: Hierarchy of the hematopoietic system. 
Based on current knowledge and understanding of the hematopoietic system, a 
simplistic model of hematopoietic hierarchy has been shown. Hematopoietic 
stem cells (HSCs) are on top of the hierarchy and can self-renew as well as 
differentiate into multipotent progenitors (MPPs). MPPs have limited self-renewal 
potential and can differentiate into myeloid or lymphoid progenitors (common 
myeloid progenitors, CMP; and common lymphoid progenitors, CLP). The 
progenitor cells can further differentiate into oligopotent and lineage-restricted 
progenitors. The lineage-restricted progenitors finally differentiate into terminally 
differentiated mature blood cells. MEP, megakaryocyte-erythroid progenitor; 
GMP, granulocyte macrophage progenitor; MkP, megakaryocyte progenitor; EP, 
erythroid progenitor; GP, granulocyte progenitor; MacP, macrophage progenitor; 
Pro DC, dendritic cell progenitor; Pro NK, natural killer cell progenitor. 
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CD150+ lower SP LSK cells have the highest self-renewal potential as well as 
bias to differentiate into myeloid lineage (Challen et al., 2010). However, these 
cells also have diminished proliferative capacity and lymphoid bias (Challen et 
al., 2010). On the other hand, CD150- SP LSK cells have maximum proliferative 
potential as well as lymphoid bias, but diminished self-renewal and myeloid bias 
(Challen et al., 2010). This study suggests that even among phenotypically 
defined HSC population, a functional diversity exists that skews the differentiation 
of HSCs towards a particular lineage. 
 In humans, the first marker that was used to identify HSCs was CD34 
(Civin et al., 1984). By using anti-My-10 mouse monoclonal antibody, they have 
shown that My-10 (CD34) is specifically expressed on immature normal human 
marrow cells as well as on hematopoietic progenitor cells (Civin et al., 1984). 
CD34 is expressed on 0.5-5% of hematopoietic cells in fetal liver, cord blood and 
bone marrow (Civin et al., 1984; DiGiusto et al., 1994; Krause et al., 1996). 
Although CD34+ cells demonstrate multi-potency or oligo-potency, they are very 
heterogeneous in nature. Next, CD90 was identified as a marker for human 
HSCs. Human BM cells that are negative for T cell, B cell, natural killer (NK) cell, 
and myeloerythroid cell specific markers (Lin-) and positive for CD34 and CD90 
(Lin-CD34+CD90+) have been shown to generate both myeloid and lymphoid 
cells when transplanted into SCID mice, whereas Lin-CD34+CD90- cells fail to do 
so (Baum et al., 1992). HSCs have been further enriched based on differential 
expression of CD38 (Baum et al., 1992; Hao et al., 1996; Petzer et al., 1996). 
CD34+CD38-HSCs, and not CD34+CD38+ HSCs, are highly enriched with cells 
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capable of initiating long-term culture in vitro and repopulating transplanted 
recipients in vivo. Furthermore, most of the Lin-CD34+CD90+ cells reside within 
the CD38- fraction (Uchida et al., 1998). This has led to the suggestion that in 
humans, Lin-CD34+CD38-CD90+ cells are highly enriched in HSCs. More 
recently, Notta et al. have demonstrated that a single Lin−CD34+CD38− 
CD45RA−CD90+RholoCD49f+ cell is able to engraft in NSG mice and can self-
renew upon serial transplantation (Notta et al., 2011).  
Role of quiescence in maintenance of HSCs: 
A key property of HSCs is their relatively low cell cycle rate, which in turn 
results in increased quiescence. Both in humans and in mice, HSCs mostly 
reside either in G0 or G1 phase of the cell cycle. Quiescence of HSCs is a 
protective mechanism that prevents their exhaustion. P21, a cyclin-dependent 
kinase inhibitor (CDKI), has been identified as a key regulator of quiescence of 
HSCs. P21 inhibits cyclin E-CDK2 activity and deficiency of p21 in HSCs results 
in reduced number of HSCs in G0 stage (Cheng et al., 2000). P21 deficient 
HSCs exhaust rapidly following serial transplantation and they are more 
susceptible to repeated myeloablaive stress (Cheng et al., 2000). Growth factor 
independent 1 (Gfi1) is a transcription factor that has been identified as a positive 
regulator of p21 expression (Duan and Horwitz, 2003). In mice deficient in Gfi1, 
the number of HSCs is increased due to increased proliferation, but display 
reduced engraftment potential (Zeng et al., 2004). In Gfi1-/- HSCs, p21 
expression level is markedly reduced compared to WT HSCs, which further 
demonstrates the importance of maintenance of quiescence in HSCs (Zeng et 
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al., 2004). Another key regulator of HSC quiescence is the Foxo group of 
proteins. Conditional deletion of Foxo1, 3 and 4 in HSCs results in increased 
cycling of the LSK population, but causes a reduction in LT-HSC number 
(Tothova et al., 2007). Foxo1/3/4 deficient mice are also more susceptible to 
repeated myeloablative stress suggesting a loss of quiescence in HSCs (Tothova 
et al., 2007). However, there are instances where increase in cell cycle does not 
result in exhaustion of HSCs. P18 deficient mice display increased HSC 
proliferation along with increase in functional HSCs that is maintained following 
serial transplantation (Yu et al., 2006; Yuan et al., 2004). Lack of p18INK4c is 
likely to result in rapid transition of HSCs to late G1 stage during which HSCs 
could be more susceptible to exhaustion. 
The importance of HSC quiescence has been further illustrated by 
studying negative regulators of HSC quiescence. Deletion of myeloid Elf-1-like 
factor (MEF) in HSCs results in increased quiescence of HSCs along with an 
increase in HSC function (Lacorazza et al., 2006). Due to their increased 
quiescence, MEF-/- HSCs recover faster from myeloablative stress compared to 
controls (Lacorazza et al., 2006). HSCs deficient in lymphocyte-specific adapter 
protein (Lnk) have increased quiescence level (Bersenev et al., 2008). However, 
the number of functional HSCs are increased in Lnk-/- mice and they have 
increased engraftment potential when transplanted in a 1:1 dilution in lethally 
irradiated mice (Bersenev et al., 2008). Proliferative cells are also susceptible to 
acquiring genetic mutations that could cause senescence (Piacibello et al., 
2005). In response to physiological stress like infection or chronic blood loss, 
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HSCs exit a quiescent state resulting in increase in proliferation and 
accumulation of DNA damage (Walter et al., 2015). Quiescence also protects 
HSCs from malignant transformation. Loss of PTEN in HSCs results in increased 
proliferation of HSCs, which subsequently results in hematologic malignancies 
(Yilmaz et al., 2006b).  
5-Fluorouracil induced stress hematopoiesis: 
  The pyrimidine analog 5-fluorouracil (5-FU) has been used extensively as 
a myeloablative reagent. Administration of 5-FU results in ablation of cycling 
cells. 5-FU is incorporated into the DNA, which is propagated among dividing 
daughter cells and causes DNA damage and results in leukopenia (Busch et al., 
2015; Lerner and Harrison, 1990). 5-FU treatment eliminates day 8 CFU-S 
population as well as BM colony-forming cells (CFC) (Randall and Weissman, 
1997). However, the primitive blast CFC as well as long-term culture initiating 
cells (LTC-IC) are either spared or generated in the initial proliferation burst to 
repopulate the hematopoietic system (Harrison and Lerner, 1991; Randall and 
Weissman, 1997). To reconstitute the hematopoietic system following 
myeloablative stress, LT-HSCs start to proliferate and differentiate into ST-HSCs. 
Busch et al. demonstrated that following myeloablative stress in mice, 7-fold 
increase in LT-HSC differentiation and proliferation corresponds to a 16-fold 
increase in ST-HSC differentiation and proliferation (Busch et al., 2015). 5-FU 
also causes changes in the expression of cell surface markers of HSCs. 
Expression level of c-Kit has been reported to be about 10-fold downregulated 
after 2 days following 5-FU treatment (Randall and Weissman, 1997). After 5-FU 
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treatment, HSCs with long-term repopulating ability, expresses Mac1 on their cell 
surface (Cheshier et al., 1999; Randall and Weissman, 1997). Studies have 
shown that HSCs, in steady state, express very low or absolutely no Mac1 
(Spangrude et al., 1988). However, following 5-FU treatment, HSCs with long-
term repopulating ability are derived from Mac1 expressing cells only (Randall 
and Weissman, 1997). After 2nd day post 5-FU treatment, HSCs enter a stage 
where they reach a higher quiescent level compared to that seen under steady-
state conditions (Venezia et al., 2004).  This state correlates with an increase in 
anti-proliferative genes like p21, Btg3; anti-migratory genes TIMP3, A-3g and 
interferon-γ -induced genes (Venezia et al., 2004). On Day 3, post 5-FU 
treatment, HSCs enter active state of cycling and start proliferating, which also 
marks the increase in expression level of genes involved in DNA replication and 
repair (Venezia et al., 2004). The number of HSCs become maximum after day 6 
post 5-FU administration. HSCs are cycling at the highest rate and this correlates 
with a significant increase in the expression of genes associated with metabolism 
and energy production (Venezia et al., 2004). Alpha4 (α4)-integrin is one of the 
key modulators of HSC proliferation at this stage (Venezia et al., 2004). Down-
regulation of α4-integrin is one of the critical step in induction of HSC proliferation 
following 5-FU treatment (Venezia et al., 2004). This time marks the shifting of 
HSCs from the quiescent niche of the bone marrow to a niche that is supportive 
of proliferation. HSCs decrease their migration by increasing cell-cell adhesion, 
which is regulated by molecules like endoglin, whose expression is highest after 
day 6 of 5-FU administration, suggesting that the adhesion of HSCs decreases 
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during this period thereby increasing their migratory potential (Venezia et al., 
2004). On day 10, HSCs migrate back to the quiescent niche within the bone 
marrow. HSCs proliferate at a reduced rate and express increased level of 
Endoglin and anti-proliferative genes such as Btg1 (Venezia et al., 2004). 
Competitive repopulation assay (CRA): 
 The ability of HSCs to home, engraft and self-renew within the bone 
marrow niche following transplant into lethally irradiated recipients has been used 
as a procedure to determine the functional potential of HSCs. Harrison first 
described the standard competitive repopulation assay (CRA) to determine HSC 
function (Harrison, 1980). In this assay, donor HSCs from test groups are mixed 
with competing HSCs derived from congenic wild type mouse and transplanted 
into lethally irradiated recipients. A standard number of competing HSCs are 
used against each test group (Harrison, 1980). Functional potential of test HSCs 
was determined by their relative ability to compete against the competitor HSCs. 
After hematopoietic reconstitution of the transplant recipients, the percentage of 
erythrocytes derived from donor and test HSCs were determined by the 
difference in electrophoretic mobility of donor and competitor hemoglobin 
(Harrison, 1980). Currently, the standard method to determine the functional 
potential of HSCs by competitive repopulation assay (CRA) uses distinct cell 
surface markers expressed by the test and competitor cells. C57BL/6 (CD45.2) 
mice and the B6.SJL-PtrcAPep3B/BoyJ (BOYJ) (CD45.1) mice differ from each 
other by the expression of CD45 on the cell surface (Shen et al., 1986). Test 
cells in different doses can be transplanted with competitor cells and following 
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transplantation contribution of the test cells and competitor cells in the peripheral 
blood of the recipients using fluorescence conjugated antibodies directed against 
cell surface antibodies can be assessed. The interpretation of this experiment 
depends on several factors including source of donor and competitor cells and 
the time of analysis after transplantation (Tothova et al., 2007). Szilvassy et al. 
used female HSCs that have undergone two round of transplantation as 
competitor cells against test cells derived from male mice (Szilvassy et al., 1990). 
However, as the competitor cells have undergone two rounds of transplantation 
previously, they became depleted of HSCs after a third round of transplantation 
and could not provide enough HSCs to compete against test cells. Freshly 
isolated bone marrow cells provide increased number of competitor HSCs as 
they have not undergone proliferative stress compared to previously transplanted 
HSCs (Janzen et al., 2006). It has been determined that in every 1X105 bone 
marrow hematopoietic cells, there are 3-4 HSCs with multilineage repopulating 
ability (Abkowitz et al., 2000; Ema et al., 2005). Another critical factor in the 
analysis of CRA is the time point of analysis following transplant. Yang et al. 
have demonstrated that 50 ST-HSCs or 50 MPPs can reconstitute myeloid and 
lymphoid lineages after 16 weeks of transplant (Yang et al., 2005). In their 
studies, ST-HSCs reconstituted >0.01% myeloid cells and >1% of lymphoid cells 
(B lymphocytes and T lymphocytes) at 16 weeks post-transplant. MPPs could 
reconstitute B cells (>0.1%) and T cells (>0.01%) along with the myeloid 
compartment after 16 weeks post-transplant (Yang et al., 2005). These data 
indicate that 16 weeks post-transplant might not be an ideal time-point to 
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determine LT-HSC functions as ST-HSCs and MPPs can contribute to the 
hematopoietic system until this time-point. More recently, Benveniste et al. 
(Benveniste et al., 2010) have demonstrated that “intermediate-term” multipotent 
HSCs, which are different from ST-HSCs and LT-HSCs, can persist and sustain 
hematopoiesis for 6-8 months following transplantation. 
The most stringent test to determine the functional potential of HSCs is to 
perform serial transplantation assays. The most immature HSCs in the 
hematopoietic hierarchy have the potential to regenerate the hematopoietic 
system of lethally irradiated hosts after serial transplantation and it can be 
sustained up to 4-5 rounds of transplantation (Ogden and Mickliem, 1976). In this 
assay, only HSCs with long-term repopulating ability will be able to self-renew 
and reconstitute the hematopoietic system of an irradiated host. 
Mixed-lineage leukemia (MLL): 
The mixed-lineage leukemia (MLL) gene encodes a DNA-binding protein 
that primarily acts as a component of the proteins associated with su(var)3-9, 
enhancer-of-zeste, trithorax (SET1) and complex of proteins associated with 
SET1 (COMPASS)-like complex (Yokoyama et al., 2004). COMPASS-like 
complexes methylate Lys4 on histone H3 (H3K4) through their conserved SET 
domain, and MLL associates with cofactors such as menin, a tumor suppressor, 
for chromatin localization and H3K4 trimethylation of genes including HOX genes 
(Yokoyama et al., 2004). In HSCs, MLL is required to maintain the quiescent 
state of HSCs. Deletion of MLL in HSCs results in reduced number of HSCs in 
G0/G1 phase of cell cycle (Jude et al., 2007). Deficiency of MLL in HSCs also 
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results in decreased engraftment of HSCs in competitive settings (Jude et al., 
2007). 
The functions of MLL gene are dysregulated due to translocation of genes 
encoding different proteins into the MLL gene. The most common translocation 
partner genes include AF4, AF6, AF9, AF10 and ENL (Eguchi et al., 2003). In 
leukemic cells, the major genomic breakpoints are clustered within an 8.3 kb 
BamHI fragment that encompasses the exon 5 to 11 of the MLL gene (Broeker et 
al., 1996a; Broeker et al., 1996b). This region has been termed as the breakpoint 
cluster region (bcr) (Broeker et al., 1996a; Broeker et al., 1996b). MLL 
translocations are identified in up to 10% of de novo acute lymphoblastic 
leukemias (ALL) and acute myeloid leukemias (AML) (Aoki et al., 2015). In 
children diagnosed with AML, rearrangements in MLL have been diagnosed in 
35-50% of patients. In AML, translocation of MLL results in loss of function of 
catalytic SET domains. The new protein, as a result of acquired translocation, 
confers the ability to recruit a histone methyltransferase, DOT1L, to target genes 
determined by specific recognition elements in the remaining portion of MLL. 
Patients with MLL rearrangements have shorter event free survival as well as 
overall survival, which together contribute to poor prognosis (Muntean and Hess, 
2012). The World Health Organization has classified leukemias with MLL 
rearrangement as a group with 4-year event-free survival of 24%-55% (Chessells 
et al., 2002; Raimondi et al., 1999; Stark et al., 2004). 
AML cells have been shown to form a functional hierarchy in which the 
leukemia initiating cells (LICs), which are at the top of this hierarchy, have the 
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potential to initiate the disease. LICs are defined as cells that when transplanted 
into immunodeficient or lethally irradiated recipients have the potential to give 
rise to disease as well as differentiate into all the cells that constitute the 
malignancy. Lapidot et al. transplanted peripheral blood cells from AML patients 
into SCID mice and showed that the frequency of LIC was 1 in 250,000 cells 
(Lapidot et al., 1994). The same study also demonstrated that when CD34+ 
CD38+ cells and CD34+ CD38- cells were isolated from the same AML patient 
and transplanted into SCID mice, CD34+ CD38+ cells engraft poorly compared 
to CD34+ CD38- mice cells thus providing further evidence about the existence 
of a functional hierarchy within AML cells (Lapidot et al., 1994). Furthermore, 
CD34+ CD38- AML cells are more quiescent compared to CD34+ CD38+ AML 
cells (Ishikawa et al., 2007). Cytosine arabinoside (Ara-C) is a standard 
chemotherapeutic agent that is used to treat AML (Lowenberg et al., 1999; 
Momparler, 1974; Reese and Schiller, 2013). Ishikawa et al. transplanted 
NOD/SCID/IL2rϒnull (NSG) mice with cells derived from AML patients and 
treated the mice with Ara-C. CD34+ CD38- cells are more resistant to Ara-C 
treatment compared to CD34+ CD38+ AML cells (Ishikawa et al., 2007). 
Moreover, CD34+ CD38- cells from Ara-C treated mice were also able to engraft 
in secondary recipients (Ishikawa et al., 2007). These data indicate that the 
quiescent state of AML LICs appears to be responsible for their chemoresistance 
property and may contribute to disease relapse. 
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Upstream regulators and downstream substrates of mechanistic target of 
rapamycin complex 1 (mTORC1): 
Mechanistic target of rapamycin (mTOR) is a serine/threonine complex 
that can be divided into two distinct complexes, mTOR complex1 (mTORC1) and 
mTOR complex2 (mTORC2) (Kaizuka et al., 2010). mTORC1 has six and 
mTORC2 has seven protein components. Both complexes share the catalytic 
mTOR subunit, mammalian lethal with sec-13 protein 8 (mLST8, GbL) DEP 
domain containing mTOR-interacting protein (DEPTOR) and the Tti1/Tel2 
complex (Kaizuka et al., 2010; Yoon et al., 2015). Regulatory-associated protein 
of mammalian target of rapamycin (raptor) and proline-rich Akt substrate 40 kDa 
(PRAS40) are specific to mTORC1, whereas rapamycin-insensitive companion of 
mTOR (rictor), mammalian stress-activated map kinase-interacting protein 1 
(mSin1), and protein observed with rictor 1 and 2 (protor1/2) are part of mTORC2 
complex (Julien et al., 2010; Sancak et al., 2007; Yoon et al., 2015). mTORC1 
activity is mainly regulated by Class IA phosphoinositide 3-kinases (PI3Ks) (Zhao 
and Vogt, 2008) (Figure 2). PI3Ks are dimers formed by regulatory (p85α, p85β, 
p55α, p55γ, and p50α) and catalytic (p110α, p110β, and p110δ) subunits. PI3K is 
recruited to the cell membrane where it converts phosphatidylinositol (4,5)-
biphosphate (PIP2) to phosphatidylinositol (3,4,5)-triphosphate (PIP3) (Zhao and 
Vogt, 2008). Akt, a protein of AGC family kinases, has three isoforms, which are 
highly conserved in nature – Akt1, Akt2 and Akt3 (Cheng et al., 1992; Jones et 
al., 1991; Masure et al., 1999). Among them, Akt1 and Akt2 are expressed at 
high levels in hematopoietic cells (Juntilla et al., 2010). PIP3 recruits 3-
18
Figure 2 
P
P
TSC1
Akt
Rheb
S6K1
mTORC1
4E-BP1
TSC2
PDK1 PTEN
P
P
P
PIP3PIP3PP
P
P
P
P
P
PI3K
19
Figure 2: The mechanistic target of rapamycin 1 (mTORC1) signaling 
pathway. 
In response to growth factors and mitogenic stimuli, phosphatidylinositol (4,5)-
biphosphate (PIP2) is converted into phosphatidylinositol (3,4,5)-triiphosphate 
(PIP3) by phosphoinositide 3-kinases (PI3K) activity. Akt binds to 
phosphatidylinositol (3,4,5)-triphosphate (PIP3) allowing 3-phosphoinositide 
dependent protein kinase-1 (PDK1) to access activation sites of Akt. Following 
phosphorylation by PDK1, activated Akt phosphorylates and inhibits tuberous 
Sclerosis 2 (TSC2)-mediated inhibition of Rheb. Activated Rheb subsequently 
phosphorylates and activates mTORC1. Activated mTORC1 phosphorylates the 
translational regulators eukaryotic translation initiation factor 4E (eIF4E)-binding 
protein 1 (4E-BP1) and ribosomal protein S6 kinase 1 (S6K1). 
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phosphoinositidedependent protein kinase-1 (PDK1) and Akt to the plasma 
membrane where PDK1 phosphorylates and activates Akt (Kandel and Hay, 
1999). The primary negative regulators of PI3K-mTORC1 pathway are 
Phosphatase and Tensin Homologue (PTEN), Tuberous Sclerosis 1 (TSC1 or 
tuberin) and Tuberous Sclerosis 2 (TSC2 or harmatin) (Figure 2). PTEN converts 
PIP3 to PIP2 (Das et al., 2003; Vazquez and Devreotes, 2006; Vazquez et al., 
2006). TSC2 is a GTPase-activating protein and it is associated with TSC1 to 
form a complex, which inactivates the small G protein Ras homolog enriched in 
brain (Rheb) (Inoki et al., 2003). Akt phosphorylates TSC2, which results in 
binding of TSC2 to 14-3-3 and subsequent reduction in GAP activity of the 
TSC1/TSC2 complex (DeYoung et al., 2008; Inoki et al., 2002; Li et al., 2002). 
Withdrawal of TSC-mediated inhibition results in increased GTP-bound Rheb 
level (DeYoung et al., 2008; Inoki et al., 2003). GTP-bound Rheb phosphorylates 
and subsequently activates mTORC1. Activated mTORC1 phosphorylates the 
translational regulators eukaryotic translation initiation factor 4E (eIF4E)-binding 
protein 1 (4E-BP1) and ribosomal protein S6 kinase 1 (S6K1) (Yang et al., 2014).  
Structure and functions of ribosomal protein S6 kinase 1 (S6K1): 
  S6K1 is a member of the cAMP-dependent protein kinases A, cGMP-
dependent protein kinases G, and phospholipid-dependent protein kinases C 
(AGC) subfamily of serine-threonine kinases (Manning et al., 2002). S6K1 
consists of 502 amino acids (Grove et al., 1991). The cellular localization of S6K1 
has been shown to be dependent on cell cycle stage and regulated by mTORC1 
(Rosner and Hengstschlager, 2011; Rosner et al., 2012). Rosner et al. 
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demonstrated that in primary human fibroblasts, S6K1 is primarily localized in the 
cytoplasm during most of the stages of cell cycle, but localizes into nucleus at 
mid G1 phase (Rosner and Hengstschlager, 2011).  
S6K1 consists of an N-terminal catalytic kinase domain, C-terminal tail 
region and C-terminal auto-inhibitory domain (AID) (Alessi, 1997; Pullen et al., 
1998). The catalytic kinase domain of S6K1 has a conserved phosphorylation 
site on the activation loop at Thr-229 (Alessi et al., 1997; Pullen et al., 1998). The 
C-terminal tail domain has two phosphorylation sites that have been termed as 
turn motif and hydrophobic motif (HM) site (Keshwani et al., 2011). On the HM 
site, the phosphorylation site is on Thr-389 (Burnett et al., 1998a; Isotani et al., 
1999). The primary kinase that phosphorylates Thr-389 is mTORC1 (Burnett et 
al., 1998a; Isotani et al., 1999). The AID has 4 phosphorylation sites (Ser-411, 
Ser-418, Thr-421, Ser-424) and blocks the phosphorylation of the kinase domain 
by activators of S6K1 (Ferrari et al., 1992). The AID domain, which is basic in 
nature, interacts and binds with acidic kinase domain and creates an inactive 
conformation (Banerjee et al., 1990; Price et al., 1991). The initial steps required 
for S6K1 activation by upstream regulators are phosphorylation of four 
phosphorylation sites on the AID that leads to a conformational change of S6K1 
and exposes the internal region of S6K1 (Burnett et al., 1998a; Burnett et al., 
1998b; Dennis et al., 1998). Subsequently, S6K1 is phosphorylated on Thr-389 
residue by mTORC1 followed by phosphorylation on Thr-229 by PDK-1 (Burnett 
et al., 1998a; Isotani et al., 1999; Pullen et al., 1998). The phosphorylation on 
Thr-389 is critical for S6K1 functions as mutation of threonine to alanine on 389 
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residue inhibits S6K1 activity (Dennis et al., 1998; Schalm and Blenis, 2002; 
Weng et al., 1998). However, for maximal activity of S6K1, phosphorylation on 
both Thr-229 and Thr-389 is required. S6K1 has been found to be inactive in 
PDK1-/- embryonic stem cells (Williams et al., 2000). Furthermore, S6K1 activity 
is abolished when the Thr-229 residue is mutated to prevent phosphorylation by 
PDK1 (Weng et al., 1998). These evidence establish that PDK1-mediated 
phosphorylation on Thr-229 is required for S6K1 activity. 
S6K1 has been identified as a negative regulator of mTORC2 activity. 
SIN1 and Rictor are two components of the mTORC2 complex and both are 
required for mTORC2-dependent phosphorylation of Akt (Yang et al., 2006). In 
mouse embryonic fibroblasts (MEF), S6K1 phosphorylates SIN1 at Thr-86 and 
Thr-398 that leads to dissociation of SIN1 from mTORC2 complex thus impairing 
mTORC2 activity (Liu et al., 2013). mTORC2 phosphorylates and activates Akt 
and in the absence of mTORC2 activity, Akt phosphorylation is diminished (Liu et 
al., 2013). In MEFs, following mTORC1-dependent activation, S6K1 also 
phosphorylates Rictor, another component of mTORC2, at Thr-1135 (Julien et 
al., 2010). Phosphorylation of Rictor at Thr-1135 results in inhibition of Akt (Julien 
et al., 2010).  Overall, these data demonstrate that activated S6K1 negatively 
regulates Akt activity by impairing the kinase activity of mTORC2. 
S6 has been identified as the primary downstream substrate of S6K1 and 
phosphorylation of S6 by S6K1 has been considered as an indicator of S6K1 
activity (Chauvin et al., 2014; Koh, 2013; Pende et al., 2004). As S6 is a critical 
regulator of protein synthesis and cell cycle progression, it has been postulated 
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that S6K1 regulates protein synthesis and cell cycle stages. However, a recent 
study by Garelick et al. demonstrated that S6K1 deficiency did not affect the 
global translational activity in muscle and liver of mice (Garelick et al., 2013).  
 S6K1 also regulates cytoskeletal reorganization by binding to F-actin in 
ovarian cancer cells (Ip et al., 2011). Furthermore, in ovarian cancer cells, S6K1 
also activates Rac1, Cdc42 and PAK1 – three critical regulators of cytoskeletal 
reorganization and cellular migration (Ip et al., 2011). However, evidence 
suggests S6K1 might regulate Rac1 and Cdc42 activity in a cell dependent 
manner. In fibroblasts, S6K1 acts downstream of Rac1 and Cdc42 (Chou and 
Blenis, 1996; Martin et al., 2001). On the other hand, in ovarian cancer cells, both 
Rac1 and Cdc42 are downstream substrates of S6K1 (Ip et al., 2011).  
 S6K1 has also been identified as a regulator of apoptosis by controlling 
the activity of different downstream substrates. S6K1 binds to and 
phosphorylates Mdm2 preventing its nuclear translocation (Lai et al., 2010). 
Mdm2 regulates ubiquination of nuclear p53 and in the absence of nuclear 
Mdm2, increased p53 level results in cell cycle arrest and cellular apoptosis (Lai 
et al., 2010). In contrast, S6K1 can also phosphorylate glycogen synthase kinase 
3 beta (GSK-3β) and pro-apoptotic protein Bcl-2 associated agonist of cell death 
(BAD) thus inhibiting apoptosis. In S6K1-/- hepatocytes, expression level of pro-
apoptotic protein caspase-8 and BH3-interacting domain death agonist (Bid) 
were significantly downregulated compared to wild-type (WT) controls (Gonzalez-
Rodriguez et al., 2009). In response to apoptotic signals, S6K1-/- hepatocytes 
have reduced cytochrome C release and reduced capase-3 activation – 
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hallmarks of apoptosis (Gonzalez-Rodriguez et al., 2009). It has been shown that 
in absence of S6K1, S6K1-dependent phosphorylation of insulin receptor 
substrate-1 (IRS-1) diminishes and results in increased IRS-1 activity (Gonzalez-
Rodriguez et al., 2009). The increase in IRS-1 activity correlates with increased 
activation of PI3K and Erk mediated pro-survival pathways (Gonzalez-Rodriguez 
et al., 2009). S6K1-deficient hepatocytes undergo apoptosis when treated with 
either PI3K or Erk inhibitor (Gonzalez-Rodriguez et al., 2009). In human colon 
adenocarcinoma cells and breast cancer cells, inhibition of S6K1 activity induces 
apoptosis (Hong et al., 2013; Song et al., 2014). Taken together, it appears that 
S6K1 can regulate different functions in different cell types utilizing distinct 
substrates. Thus, it is essential to assess the role of S6K1 in a cell dependent 
manner.  
 
 
 
 
 
 
 
 
 
 
 
25
Summary and significance: 
Conventional chemotherapeutic measures to treat AML are beneficial for a 
minority of patients (Buchner et al., 2012). Furthermore, due to toxic effects, 
chemotherapies have limited use to treat elderly and patients with comorbidities 
(Buchner et al., 2012). Following treatment with chemotherapeutic agents like 
mitoxantrone, etoposide, and cytarabine, patients show signs of drug-induced 
toxicities including diarrhea, neutropenic infection and transaminase elevation 
(Greenberg et al., 2004; Tallman et al., 1999). Treatment with mTORC1 inhibitor, 
sirolimus, causes toxicities which include headache, stomatitis, hyperlipidemia 
and mild thrombocytopenia in patients (MacDonald and Group, 2001; Saunders 
et al., 2001). In view of the above facts, it is imperative to identify a downstream 
target of mTORC1 to develop pharmacological inhibitors that will show minimal 
toxicities in patients. Previously, different studies have identified that upstream 
effectors of S6K1 are critical regulators of hematopoiesis and leukemogenesis 
(Guo et al., 2013; Haneline et al., 2006; Juntilla et al., 2010; Kharas et al., 2010; 
Lee et al., 2010; Magee et al., 2012; Yilmaz et al., 2006b). In response to growth 
factors and other mitogenic stimuli, S6K1 is phosphorylated and activated by 
mTORC1 (Burnett et al., 1998a; Fang et al., 2003). Multiple line of evidences 
have shown that mTORC1 is expressed in HSCs as well as in AML cells and 
critical for their functions (Guo et al., 2013; Sujobert et al., 2015; Zeng et al., 
2012). However, the exact role of S6K1 in both hematopoiesis and 
leukemogenesis is not known yet. The main objective of this study was to 
determine the role of S6K1 in development and function of HSCs as well as 
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Figure 3: Schematic models of proposed specific aims in the study. 
(A) Determining the role of S6K1 on development, differentiation and quiescence 
of HSCs using a genetic model of S6K1-deficient (S6K1-/-) mouse. (B) 
Determining the role of S6K1 on regeneration of hematopoiesis and quiescence 
of HSCs following myeloablative stress. (C) Determining the effect of modulation 
of S6K1 expression level on self-renewal of HSCs using loss-of-expression and 
overexpression approaches. (D) Determining the role of S6K1 on initiation, 
progression and propagation of leukemia. 
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initiation, development and propagation of AML. 
Our studies specifically address the following aims: 
  Specific aim 1: We hypothesized that S6K1 regulates development and 
differentiation of HSCs to maintain steady-state hematopoiesis. We have 
determined the role of S6K1 in regulation of HSC as well as HSC/P frequency 
and number using a genetic approach (Figure 3A).  
  Specific aim 2: We hypothesized that S6K1 regulates quiescence of 
HSCs and the recovery of hematopoietic system following myeloablation. We 
have determined the role of S6K1 in regulation of regeneration of hematopoietic 
system following myeloablative stress (Figure 3B). 
  Specific aim 3: We hypothesized that S6K1 expression level regulates 
engraftment, differentiation and self-renewal potential of HSCs. We have 
determined the effect of S6K1 deficiency as well as hyperactivation of S6K1 on 
HSC function using genetic approaches and serial transplantation models (Figure 
3C). 
  Specific aim 4: We hypothesized that S6K1 is a key regulator of initiation, 
development and propagation of AML. We have determined the role of S6K1 in a 
MLL-AF9 translocation driven leukemia model using genetic approaches and 
serial transplantation models (Figure 3D). 
 Overall our studies revealed that S6K1 regulates self-renewal of HSC 
as well as AML cells. Deficiency of S6K1 results in reduced quiescence of 
HSCs. Following myeloablative stress, S6K1 deficiency delays HSCs return 
to the quiescent state. Using genetic approaches, we have also 
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demonstrated that S6K1 expression level is critical for maintenance of HSC 
function. In our studies, dysregulation of S6K1 expression level results in 
reduced self-renewal of HSCs. Furthermore, we have also shown that S6K1 
is a positive regulator of p21 expression and deficiency of S6K1 results in 
reduced p21 level in HSCs. We have also identified S6K1 as a therapeutic 
target to delay the propagation of AML. Our studies have provided 
compelling evidence that loss of expression of S6K1 in AML cells results in 
delayed propagation of AML in secondary recipients. Furthermore, our 
studies also revealed that pharmacological inhibition of S6K1 activity 
causes inhibition of growth of human leukemic cells. 
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Chapter 2: Materials and Methods 
 
Mice: 
C57BL/6 (CD45.2) mice were purchased from Jackson Laboratories (Bar 
Harbor, ME). B6.SJL-PtrcAPep3B/BoyJ (BOYJ) (CD45.1) and C57BL/6 X BOYJ-
F1 (CD45.1/CD45.2) mice were obtained from the In Vivo Therapeutics (IVT) 
Core of Indiana University School of Medicine (Indianapolis, IN). S6K1-/- mice 
were obtained from University of Cincinnati (Cincinnati, OH) and were bred and 
maintained in-house. Mice used in transplantation studies received doxycycline 
feeds for 30 days post-irradiation. All protocols were approved by the Institutional 
Animal Care and Use Committee (IACUC) of Indiana University School of 
Medicine. 
Antibodies, cytokines and other reagents: 
Antibody against S6K1 was purchased from BD Biosciences (San Jose, 
CA). Antibodies against phosphorylated forms of S6K1, S6, 4E-BP1, mTOR and 
Akt were purchased from Cell Signaling Technology (Danvers, MA). Antibody 
against β-actin was purchased from Sigma (St. Louis, MO). Murine interleukin-6 
(mIL-6), murine thrombopoietin (mTPO), murine interleukin-3 (mIL-3), murine 
stem cell factor (mSCF), murine FLT3 ligand (mFLT3L), human insulin-like 
growth factor-2 (hIGF2), human fibroblast growth factor-acidic (hFGF), human 
interleukin-6 (hIL-6), human thrombopoietin (hTPO), human interleukin-3 (hIL-3), 
human stem cell factor (hSCF) and human FLT3 ligand (hFLT3L) were 
purchased from Peprotech (Rocky Hill, NJ). PF-4708671, S6K1 inhibitor, was 
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purchased from Tocris (Bristol, UK). 5-FU was purchased from APP 
Pharmaceuticals (Schaumburg, IL). The fluorochrome conjugates and clones of 
antibodies used for flow cytometry are described in Table 1. Fluorochrome 
conjugated antibodies against CD150 and CD48 were purchased from 
BioLegend (San Diego, CA). Fluorochrome conjugated antibodies against CD34 
and CD16/32 were purchased from eBioscience (San Diego, CA). Fluorochrome 
conjugated antibodies against c-Kit, Sca1, B220, Ter119, CD11b, Ly6C and 6G, 
CD3, CD4, CD8, CD19, CD45.1 and CD45.2 were purchased from BD 
Biosciences. Iscove’s Modified Dulbecco’s Medium (IMDM) was purchased from 
Thermo Fisher Scientific. StemSpan serum-free expansion medium (StemSpan-
SFEM) was purchased from StemCell Technologies (Vancouver, BC, Canada). 
Fetal Bovine Serum (FBS) was purchased from GE Healthcare Life Sciences 
(Pittsburgh, PA). Rat serum and bovine serum albumin (BSA) was purchased 
from Sigma. Human umbilical cord blood (UCB) derived CD34+ cells were 
obtained from Indiana University Melvin and Bren Simon Cancer Center Angio 
BioCore with Institutional Review Board’s (IRB) approval.  
Cell culture: 
Human leukemic cell line MA9-3 was obtained from University of 
Cincinnati (Cincinnati, OH). Cells were cultured in IMDM in the presence of 20% 
FBS and supplemented with hSCF, hIL-3, hIL-6, hFlt-3L, and hTPO (10 ng/ml of 
each cytokine). UCB derived CD34+ cells were cultured in StemSpan-SFEM in 
presence of 10 ng/ml hSCF, 20 ng/ml hTPO, 20 ng/ml hIGF-2 and 10 ng/ml 
hFGF. 
32
Thymidine incorporation assay: 
Cells were washed with IMDM containing 0.2% BSA and cultured in 
serum-free media for 6 hours. After 6 hours, cells were collected, centrifuged and 
resuspended in IMDM containing 20% FBS. 5X104 cells were plated in each well 
of a 96-well plate. Cells were incubated for 42 hours and subsequently pulsed 
with 1.0 µCi (0.037 MBq) [3H] thymidine (Perkin Elmer, Waltham MA) for 6 hours. 
Cells were harvested using an automated 96-well cell harvester (Brandel, 
Gaithersburg, MD) and thymidine incorporation was determined as counts per 
minute (CPM). 
Apoptosis assay: 
MA9-3 cells were washed with IMDM containing 0.2% BSA and cultured in 
serum-free IMDM for 6 hours. After 6 hours, cells were collected, centrifuged and 
resuspended in IMDM containing 20% FBS. 2X105 cells were plated in each well 
of a 24-well plate at a final volume of 1 ml. Cells were incubated for 18 hours in 
presence or absence of PF-4708671. After 18 hours, cells were collected, 
centrifuged and resuspended in Annexin V binding buffer (BD Biosciences). Cells 
were incubated with APC-conjugated Annexin V (BD Biosciences) for 20 minutes 
on ice. Cells were washed and incubated with 7-Aminoactinomycin D (7-AAD; 
BD Biosciences). Cells were acquired in LSR II flow cytometer machine (BD 
Biosciences). Data analysis was performed using FlowJo software (FlowJo, 
Ashland, OR).  
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Isolation of bone marrow mono nuclear cells: 
Mice were humanely euthanized and two femurs, two tibias and two iliac 
crests were surgically removed. Whole BM cells were flushed using IMDM with a 
23G syringe, centrifuged at 1500 r.p.m. for 5 minutes and the supernatant was 
discarded. To obtain mono nuclear cells (MNCs), RBC lysis was performed using 
RBC lysis buffer (eBioscience). Whole BM cells were incubated in 1 ml of RBC 
lysis buffer for 5 minutes at room temperature. After 5 minutes, cells were 
centrifuged at 1500 r.p.m. for 5 minutes. The supernatant was discarded and 
cells were resuspended in PBS containing 0.2% BSA to obtain a single cell 
suspension. 
Analysis of murine hematopoietic stem and progenitor cells: 
  For detection of HSCs and HPCs, BM MNCs were resuspended in 
blocking buffer (10% rat serum and 0.2% BSA in PBS) and incubated on ice for 
30 minutes to prevent non-specific binding. To detect SLAM LSK cells, we used 
Gr1, Mac1, B220, Ter119, CD3, CD4 and CD8 as lineage markers along with 
CD150, CD48, c-Kit and Sca1. For GMP, CMP and MEP, CD34, CD16/32, c-Kit 
and Sca1 were used along with lineage markers as described above. Cells were 
incubated with antibodies on ice for 30 minutes. Cells were washed with 0.2% 
BSA in PBS and analyzed using LSRII flow cytometer machine. Data analysis 
was performed using FlowJo software.  
To detect Ki-67 positive cells in SLAM LSK cells, BM MNCs were stained 
for surface markers as described above. After staining, cells were washed with 
0.2% BSA in PBS, permeabilized and fixed using Cytofix/Cytoperm buffer (BD 
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Biosciences, Franklin Lakes, NJ) and incubated with antibody against Ki-67 for 
30 minutes on ice. Cells were washed, incubated with 4′,6-diamidino-2-
phenylindole (DAPI) (Sigma) and acquired using LSR II flow cytometer machine. 
Data analysis was performed using FlowJo software. 
Sorting of HSCs and HSC/Ps:  
Whole BM cells were aseptically isolated from WT and S6K1-/- mice and 
single cell suspension of MNCs were obtained as described above. MNCs were 
incubated with biotin-conjugated B220, CD11b, CD3, Ter119, Ly6G and 6C for 
30 minutes on ice. Streptavidin Microbeads (Miltenyi Biotec, San Diego, CA) 
were added into the cell solution at a concentration of 10 µl/107 cells and 
incubated for 15 minutes on ice. Tubes containing labelled cells were inserted 
into a magnet block and cell suspension was collected. Cell suspension was 
centrifuged at 1500 r.p.m. for 5 minutes and the supernatant was discarded. 
Cells were resupended in blocking buffer and stained for cell surface markers as 
described above. Cells were washed and resuspended in PBS containing 0.2% 
BSA. Cells were sorted based on the cell surface markers using BD FACSARIA 
III (BD Biosciences). Cells, which were sorted for RNA isolation, were sorted into 
tubes containing 350 µl of Buffer RLT plus (Qiagen, Hilden, Germany). Cells 
used for transplantation studies were sorted into tubes containing PBS-BSA. 
Quantitative polymerase chain reaction:  
Cells were loaded on QIAshredder (Qiagen) and centrifuged at 13500 
r.p.m. for 2 minutes. The flow through was collected and total RNA was isolated 
from cells using RNeasy Plus Micro kit (Qiagen) according to manufacturer’s 
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instructions. Isolated RNA was reverse transcribed using random hexamers and 
SuperScript III First-Strand Synthesis System (Life Technologies, Carlsbad, CA) 
according to manufacturer’s instructions. Primers for SYBR Green qRT-PCR 
were designed to produce an amplicon size of 80-150 base pairs (Table 2). qRT-
PCR was performed using FastStart Universal SYBR Green Master with ROX 
(Roche, Basel, Switzerland) using a 7500 Real-Time PCR System (Applied 
Biosystems, Foster City, CA) for 40 cycles. All samples were run in either 
triplicates or quadruplicates. Actb (encoding β-actin) was used for normalization 
of samples. 
Competitive repopulation assay with BM MNCs: 
Whole BM cells were aseptically isolated from WT and S6K1-/- mice and 
single cell suspension of MNCs were obtained as described above. Freshly 
isolated 5X105 BM MNCs from either WT or S6K1-/- mice were mixed with 
freshly isolated 5X105 competitor BM MNCs from BoyJ mice. C57BL/6 X BOYJ-
F1 recipients were lethally irradiated at 1100 cGy from a cesium source using a 
split dose of 700 cGY and 400 cGy at an interval of 4 hours. Cells were injected 
intravenously into the recipients. Engraftment of donor-derived cells (CD45.2+) 
was monitored in the peripheral blood of recipients at 4 week intervals. Data 
analysis was performed using FlowJo software. For secondary transplants, BM 
MNCs were isolated aseptically from primary transplant recipients at 24 weeks 
after primary transplant and 1x106 MNCs were injected intravenously into lethally 
irradiated C57BL/6 X BOYJ-F1 recipients. For all the transplantation 
experiments, cells were resuspended in PBS containing 0.2% BSA. For both 
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primary and secondary transplants, cells were resuspended at a final 
concentration of 5X106 cells/ml and 200 µl of cell solution was used for 
transplantation into each individual mouse. 
Competitive repopulation assay with SLAM LSK cells: 
Whole BM cells were aseptically isolated from WT and S6K1-/- mice and 
single cell suspension of MNCs were obtained as described above. SLAM LSK 
cells were sorted as described above. For primary transplant, 250 SLAM LSKs 
from either WT or S6K1-/- mice were mixed with freshly isolated 3X105 
competitor BM MNCs from BoyJ mice. C57BL/6 X BOYJ-F1 recipients were 
lethally irradiated as described above. Cells were injected intravenously into the 
recipients. For secondary transplants, BM MNCs were isolated aseptically from 
primary transplant recipients on 24 weeks post-transplant and one million cells 
were injected intravenously into lethally irradiated C57Bl/6 X BOYJ-F1 recipients. 
For tertiary transplants, BM MNCs were isolated aseptically from secondary 
transplant recipients on 24 weeks post-transplant and 2.5x106 cells were injected 
intravenously into lethally irradiated C57BL/6 X BOYJ-F1 recipients. Engraftment 
of donor-derived cells (CD45.2+) were monitored in the peripheral blood of the 
recipients at 4 week intervals. Data analysis was performed using FlowJo 
software. 200 µl of cell solution was used for transplantation into each individual 
mouse. 
Analysis of peripheral blood from transplant recipients: 
Peripheral blood from the transplant recipients was collected by tail-vein 
bleeding into heparinized microcapillary tubes (Fisher Scientific, Waltham, MA). 
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RBCs were lysed by treating with RBC lysis buffer (eBioscience). Cells were 
washed with PBS and resuspended in blocking buffer (10% rat serum and 2% 
BSA in PBS). Cells were incubated on ice for 30 minutes for blocking. Cells were 
stained with the following antibodies: FITC conjugated anti-CD45.1, APC 
conjugated anti-CD45.2, Pacific Blue conjugated anti-B220, PE-conjugated 
Mac1, APC-Cy7-conjugated Gr1 and PerCpCy5.5-conjugated CD3. Cells were 
incubated with antibodies on ice for 30 minutes. Cells were washed with 0.2% 
BSA in PBS and acquired using LSR II flow cytometry machine. Data analysis 
was performed using FlowJo software. 
Homing assay: 
Whole BM cells were aseptically isolated from WT and S6K1-/- mice and 
single cell suspension of MNCs were obtained as described above. MNCs were 
resuspended at a concentration of 1X106 cells/ml in 0.2% BSA in IMDM.  DiD 
(1,1’-dioctadecyl-3,3,3’,3’-tetramethylindodicarbocyanine) cell-labeling solution 
(Life Technologies, Carlsbad, CA) was added to the cell suspension at a 
concentration of 4 µl/ml and incubated for 30 minutes at 37oC. Labelled cells 
were centrifuged at 1500 r.p.m. for 5 minutes and supernatant was discarded. 
Cells were resuspended at a concentration of 50X06 cells/ml in PBS containing 
0.2% BSA.  Lethally irradiated Boy/J mice were injected intravenously with 107 
Did-labeled MNCs. After 18 hours, recipient mice were euthanized and BM 
MNCs were isolated as described above. MNCs were stained for lineage 
markers as well as for c-Kit and Sca1 as described above. Homing of DiD+ LSK 
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cells were acquired using LSRII flow cytometry machine. Data analysis was 
performed using FlowJo software. 
5-FU treatment: 
   Eight to twelve weeks old WT and S6K1-/- mice were injected intra-
peritoneally with 5-FU (150 mg/kg body wt.) on day zero of the experiment. On 
day 6, 9, and 15 after 5-FU treatment, mice were euthanized and BM MNCs were 
isolated as described above. BM MNCs were stained for lineage markers as well 
as c-Kit and Sca1 as described above. BM MNCs were analyzed by flow 
cytometry as described above.  
BrdU incorporation assay:  
 WT and S6K1-/- mice were injected with 1mg of BrdU (BD 
Biosciences) intraperitoneally after day 8 following 5-FU injection. Injected mice 
were euthanized after 16 hours. BM MNCs were isolated as described above. 
BM MNCs were resuspended in blocking buffer (10% rat serum and 0.2% BSA in 
PBS) and incubated on ice for 30 minutes for blocking. To detect LSK cells, we 
used Gr1, Mac1, B220, Ter119, CD3, CD4 and CD8 as lineage markers along 
with c-Kit and Sca1. Cell surface staining was done as described before and cells 
were washed by resuspending in 2% BSA in PBS followed by centrifugation at 
1500 r.p.m. for 5 minutes. The supernatant was discarded and cells were 
resuspended in Cytofix/Cytoperm buffer (BD Biosciences) for 30 minutes on ice. 
Cells were washed with BD Perm/Wash buffer and resuspended in Cytoperm 
Permeabilization Buffer Plus. Cells were incubated for 10 minutes on ice and 
washed with BD Perm/Wash buffer. Cells were resuspended in Cytofix/Cytoperm 
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buffer for 5 minutes on ice and washed with Perm/Wash buffer. Cells were 
resupended in 100 µl of DPBS containing 300 µg/ml of DNase. Cells were 
incubated in 37oC for 30 minutes and washed with BD Perm/Wash buffer. Cells 
were incubated with APC-conjugated anti-BrdU antibody for 30 minutes on ice. 
Cells were washed with BD Perm/Wash buffer. Cells were incubated with 7-AAD 
and were aacquired by LSR II flow cytometry machine. Data analysis was 
performed using FlowJo software. 
Transplantation of HSC/Ps following 5-FU treatment:  
Eight to twelve weeks old WT and S6K1-/- mice were injected 
intraperitoneally with 5-FU (150 mg/kg body wt.) on day zero of the experiment. 
After 6 days post 5-FU treatment, mice were euthanized and WBM cells were 
aseptically isolated as described above. Following RBC lysis, 0.1 million BM 
MNCs from either WT or S6K1-/- mice were mixed with freshly isolated 
competitor cells from BoyJ mice. BoyJ recipients were lethally irradiated as 
described above. Cells were injected intravenously into the recipients. 
Engraftment of donor-derived cells (CD45.2+) were monitored in the peripheral 
blood of the recipients at 1, 2, 3, and 4 months post-transplant as described 
previously. Data analysis was performed using FlowJo software. 
Generation of retroviral supernatants and retroviral transduction: 
  Retroviral supernatants for the transduction of BM MNCs were generated 
using the Phoenix ecotropic packaging cell line transfected with retroviral vector 
plasmids using a calcium phosphatase transfection kit (Promega, Madison, WI). 
After 48 hours of transfection, supernatants were collected and filtered through 
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0.45 µm membrane (GE Healthcare Life Sciences). BM MNCs were isolated as 
described above and cultured in IMDM supplemented with FBS, mIL-6 (10 
ng/ml), mFLT3L (10 ng/ml), mTPO (50ng/ml) and mSCF (50 ng/ml) for overnight. 
For transduction, cells were cultured for 48 hours in the presence of retroviral 
supernatant on tissue culture plates coated with retronectin (Takara Bio Inc, 
Otsu, Japan). After 48 hours, cells were withdrawn from retroviral supernatants 
and sorted based on GFP expression using FACS ARIA III. 
Leukemogenesis assay: 
8-12 weeks old WT and S6K1-/- mice were injected intraperitoneally with 
5-FU (150 mg/kg body wt.). After 5 days, BM MNCs were aseptically isolated as 
described above. Cells were incubated overnight in IMDM containing 20% FBS 
along with mIL-3 (10 ng/ml), mIL-6 (10 ng/ml) and mSCF (100 ng/ml). Cells were 
transduced with MLL-AF9 as described above. Cells were sorted to homogeneity 
based on GFP expression using FACS. One million sorted cells were injected 
intravenously into lethally irradiated C57/BL6 mice. For secondary transplant, 
MNCs were isolated from the spleens of primary transplant recipients with AML. 
One million MNCs were injected intravenously into lethally irradiated C57/BL6 
mice. 
Western blotting: 
 WT and S6K1-/- BM MNCs were transduced with either retroviral 
empty vector or retrovirus encoding MLL-AF9 as described above. Sorted cells 
were starved in serum and growth factor free IMDM containing 0.2% BSA for 6 
hours. Cells were lysed using CelLytic buffer (Sigma) supplemented with 
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protease inhibitor (Roche) as per manufacturer’s instructions. Cell lysates were 
cleared by centrifugation at 13500 r.p.m. for 12 minutes and the supernatant was 
collected. Protein was quantified by bicinchoninic acid assay (BCA assay) by 
using Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA) 
according to manufacturer’s instructions. Equal amount of protein was boiled in 
4X Laemmli sample buffer (Bio-Rad, Hercules, CA) at 95oC for 5 minutes. 
Proteins were separated by SDS-PAGE using Novex Tris-Glycine gels (Thermo 
Fisher Scientific) and transferred electrophoretically onto a nitrocellulose 
membrane. Membranes were incubated with blok-CH (Millipore, Norwood, OH) 
to prevent non-specific binding. Membranes were incubated with primary 
antibodies followed by horseradish peroxidase-conjugated secondary antibodies. 
Blots were developed using Luminata Forte (Millipore) and images were captured 
using Universal Hood II imager (Bio-Rad). 
Statistical analysis: 
The means of two groups were compared by two-tailed t tests. The 
means of multiple groups were compared by one-way ANOVA with Bonferroni 
post-hoc analysis. P values less than 0.05 were considered statistically 
significant. 
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Table 1: Antibodies used for flow cytometry 
Antibody Clone Conjugate 
CD150 TC15-12F12.2 APC 
CD48 HM48-1 APC-Cy7 
c-Kit 2B8 BV421 
c-Kit 2B8 BV450 
c-Kit 2B8 Pacific Blue 
c-Kit 2B8 APC 
Ly-6A/E E13-161.7 FITC 
Ly-6A/E E13-161.7 PE-Cy7 
Ly-6G and Ly-6C RB6-8C5 APC-Cy7 
Ly-6G and Ly-6C RB6-8C5 PE 
B220 RA3-6B2 PE 
CD11b M1/70 PE 
TER-119 TER-119 PE 
CD3 17A2 PE 
CD4 GK1.5 PE 
CD8 53-6.7 PE 
CD16/CD32 93 PerCP-Cy5.5 
CD34 RAM34 Pacific Blue 
CD19 1D3 APC 
CD45.1 A20 FITC 
CD45.2 104 APC 
CD3 17A2 PerCP-Cy5.5 
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Table 2: Primer sequences used for qRT-PCR 
Target Sequence 
S6K1 fwd TCTGAGGATGAGCTGGAGGAG 
S6K1 rev TCACAATGTTCCATGCCAAGT 
  
p21 fwd AACATCTCAGGGCCGAAAAC 
p21 rev TCCTGACCCACAGCAGAAGA 
  
p27 fwd CAGTGTCCAGGGATGAGGAAG 
p27 rev TTCGGGGAACCGTCTGAAA 
  
p130 fwd TGGCATGGAAAACCAAGTCC 
p130 rev CAAGTCCTCCAGCATCAGCA 
  
Hoxa9 fwd CTTCAGTCCTTGCAGCTTCCA 
Hoxa9 rev TCCTTCTCAGTTCCAGCGTCT 
  
Bmi1 fwd CAGGTTCACAAAACCAGACCAC 
Bmi1 rev TGACGGGTGAGCTGCATAAA 
  
Foxo3 fwd ACTCCAAGACCTGCTTGCTTC 
Foxo3 rev AAGGACATCATTGGATCGTTG 
  
PTEN fwd GATTACAGACCCGTGGCACT 
PTEN rev ATCACCACACACAGGCAATG 
  
PU1 fwd GGATCTGACCAACCTGGAG 
PU1 rev CTACTACTCCTTCGTGGGCAG 
  
Cyclin B2 fwd GTGAAACCAGTGCAGATGGAG 
Cyclin B2 rev GCAGAGCAGAGCATCAGAGAA 
  
Cyclin D1 fwd CCAGAGGCGGATGAGAACA 
Cyclin D1 rev TGCGGTAGCAGGAGAGGAAG 
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Cyclin D3 fwd TGCGTGCAAAAGGAGATCAAG 
Cyclin D3 rev AGTTCATAGCCAGAGGGAAGACA 
  
Cyclin E1 fwd GATTGGCTGATGGAGGTGTG 
Cyclin E1 rev TGGTGCAACTTTGGAGGGTA 
  
Cyclin G1 fwd CGGAGACATTTTCCCTAGCTGT 
Cyclin G1 rev CCTTTCCTCTTCAGTCGCTTTC 
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Chapter 3: Role of S6K1 in regulation of steady-state hematopoiesis 
 
Introduction: 
Activation of S6K1 in response to different stimuli including growth factors 
is mediated through PI3K, Akt and mTORC1. PI3K is the upstream regulator of 
Akt and mTORC1 activation. Deficiency of p85α, but not p85β, subunit of PI3K 
results in reduced cellularity in fetal liver (Haneline et al., 2006). The reduction in 
cellularity is further increased when both p85α and p85β subunits are deleted. 
The deficiency of p85α subunit results in reduced BFU-E, CFU-E, CFU-GM and 
CFU-MEG formed by fetal liver hematopoietic cells compared to WT fetal liver 
hematopoietic cells. Fetal liver HPCs deficient in either p85α subunit or both 
p85α and p85β subunit showed reduced proliferation in response to SCF 
compared to WT controls (Haneline et al., 2006). 
 Downstream of PI3K, deficiency of Akt1 and Akt2 results in increased 
frequency of HSCs in fetal liver and bone marrow. However, in mice deficient in 
Akt1 and Akt2, myeloid, B and T cells are markedly reduced compared to WT 
mice (Juntilla et al., 2010). Akt1 and Akt2 deficient HSCs show increased 
quiescence level whereas the apoptosis level in MPPs are increased (Juntilla et 
al., 2010). It has also been shown that Akt1 and Akt2 help to maintain a critical 
balance of ROS level in HSCs, which in turn regulates differentiation and 
proliferation of HSCs (Juntilla et al., 2010).  
Deletion of mTOR in adult mice results in reduced count in neutrophils and 
monocytes, which contributes to an overall decrease in WBCs when compared to 
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controls (Guo et al., 2013). Furthermore, the platelet count as wells as RBCs and 
hemoglobin level were decreased in the peripheral blood of mTOR-/- mice (Guo 
et al., 2013). The absolute number of HSCs were increased in mTOR-/- mice, 
which was associated with increased cell cycling (Guo et al., 2013). Bone 
marrow cellularity as well as absolute number of myeloid cells and different 
subsets of B lymphocytes (pre/pro B cells, immature B cells and mature B cells) 
were significantly reduced in the BM of mTOR-/- mice (Guo et al., 2013). This 
reduction in absolute number was associated with an increase in apoptosis of 
myeloid and lymphoid cells in mTOR deficient mice (Guo et al., 2013). 
Furthermore, the absolute number of CMPs was decreased in mTOR-/- mice 
along with an increase in CLPs (Guo et al., 2013). Lineage negative cells derived 
from bone marrow of mTOR-/- mice showed reduced activation of S6K1 (Guo et 
al., 2013). These data suggest that mTOR mediated S6K1 activation might play a 
critical role in development and maintenance of HSCs and HPCs. In another 
study, treatment with rapamycin increased the number of LSK cells when murine 
HSCs were cultured ex-vivo (Luo et al., 2014). Rapamycin also increases the 
CAFC number of ex-vivo cultured murine HSCs. However, although the roles of 
PI3K, Akt and mTOR in development and maintenance of HSCs and HPCs are 
known, the role of S6K1 in this aspect is hitherto unknown.  
In this chapter, we show that deficiency of S6K1 results in reduced overall 
BM cellularity and phenotypically defined HSC number. We also show that S6K1 
is a regulator of HSC quiescence and following deficiency of S6K1, HSCs have 
reduced expression of p21. We further provide evidence that the reduction in the 
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absolute hematopoietic cell number in S6K1-/- mice is not due to the loss of 
expression of S6K1 in the hematopoietic niche. 
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Results: 
S6K1 is expressed in HSCs and HPCs:  
  Previous studies have demonstrated that S6, a downstream substrate of 
S6K1, is expressed and activated in HSCs and HPCs (Magee et al., 2012). 
However, as S6 can be activated by S6K2 too (Pende et al., 2004), activation of 
S6 is not an appropriate indicator of S6K1 activity and expression. We sorted 
HSCs, HPCs and mature hematopoietic cells based on cell surface expression of 
markers and analyzed the expression level of S6K1 in these subsets by qRT-
PCR. We found that S6K1 is expressed in HSCs as well as in MPPs and mature 
hematopoietic cells (Figure 4A). However, when S6K1 expression is normalized 
relative to the expression level of HSCs, GMPs and MEPs have significantly 
increased S6K1 expression whereas S6K1 expression in mature myeloid cells is 
significantly decreased (Figure 4A). We did not observe any significant change in 
expression level of S6K1 in MPPs, CLPs, CMPs and B lymphocytes relative to 
HSCs (Figure 4A). 
S6K1-/- mice have reduced BM MNCs and HSCs: 
 Previous studies have linked mTORC1 activity with absolute 
hematopoietic cell numbers (Guo et al., 2013). To determine the effect of S6K1 
deficiency on absolute hematopoietic cell numbers, we isolated BM MNCs from 
age-matched and sex-matched WT and S6K1-/- mice. S6K1-/- mice had 
significantly reduced BM MNCs compared to WT controls (Figure 4B). Based on 
expression of CD150 and CD48, LSK cells can be broadly divided into HSCs and 
MPPs (Figure 5A). In S6K1-/- mice, there was no change in the frequency of 
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Figure 4: Expression level of S6K1 in HSCs and HPCs and effect of S6K1 
deficiency on absolute number of mono nuclear cells in bone marrow. 
(A) Expression of S6K1 in HSCs, HPCs and mature effector cells as determined 
by qRT-PCR. BM MNCs were isolated from WT mice and stained for cell surface 
markers to identify HSC, MPP, GMP, CMP, MEP, CLP, mature myeloid cells and 
B cells. Cells were sorted using flow cytometry and total RNA was isolated. 
cDNA was synthesized from total RNA using reverse transcriptase. Using SYBR 
Green Master mix and primers designed to specifically amplify murine S6K1, 
expression level of S6K1 in each subset was determined. S6K1 expression level 
in each subset was normalized to β-actin expression and expressed as values 
relative to HSCs. Experiment was performed in quadruplicate. Data are 
expressed as mean ± SD; *p<0.05. (B) BM MNCs were isolated from WT and 
S6K1-/- mice and total number of MNCs in two femurs, two tibias, and two iliac 
crests was determined. n=4-5 mice in each group. Data are expressed as mean 
± SEM; *p<0.05. 
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Figure 5: S6K1-/- mice have reduced HSCs. 
(A) Representative dot plot of BM HSCs (CD150+ CD48- LSK cells) gated on 
LSK cells of WT and S6K1-/- mice. (B) Frequency of HSCs (CD150+ CD48- 
LSK), MPPs (CD150- CD48- LSK) populations in WT and S6K1-/- mice were 
determined by flow cytometry. (C) Absolute numbers of HSCs and MPPs in 
two femurs, two tibias and two iliac crests of WT and S6K1-/- mice. n=4-5 mice 
in each group. Data are expressed as mean ± SEM; *p<0.05. 
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HSCs compared to WT (Figure 5B). However, the frequency of MPPs were 
significantly reduced in S6K1-/- mice compared to WT controls (Figure 5B). In 
terms of absolute cell numbers, S6K1-/- mice have significantly reduced HSCs 
and MPPs compared to WT controls (Figure 5C).  
S6K1 is a positive regulator of HSC quiescence: 
  Ki-67, a nuclear nonhistone protein, is present in the nuclei of cells in the 
G1, S and G2 phase of cell cycle and absent in the cells that are in G0 phase 
(Gerdes et al., 1984; Gerdes et al., 1991). This unique property of this protein 
has been used to identify quiescent cells in the bone marrow. We stained HSCs 
from WT and S6K1-/- mice to determine the effect of S6K1 deficiency on 
quiescence of HSCs. The frequency of Ki-67 negative cells in S6K1-/- HSCs was 
significantly decreased compared to WT LT-HSCs (Figure 6A). As these data 
indicate that the HSCs in S6K1-/- mice were less quiescent, we next examined 
expression level of different genes known to regulate quiescence in HSCs. The 
expression of p21 was significantly reduced in S6K1-/- HSCs compared to WT 
controls (Figure 6B). However, we did not find any change in mRNA expression 
level of p27, p130, PTEN, Bmi1 and Hoxa9 expression in S6K1-/- HSCs. 
S6K1 regulates frequency and absolute number of HPCs and terminally 
differentiated cells: 
 Previous studies on mTOR-/- mice have shown that mTOR deficiency 
results in reduced number of CMPs as well as myeloid and B cells in bone 
marrow (Guo et al., 2013). These data indicate that S6K1 activity might be a 
critical regulator of hematopoietic progenitor and terminally differentiated cell 
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Figure 6: S6K1 deficiency results in reduced quiescence of HSCs. 
(A) Quantitative representation of frequency of Ki-67 negative BM HSCs 
(CD150+ CD48- LSK cells) in WT and S6K1-/- mice. n=4-5 mice in each 
group. Data are expressed as mean ± SEM; *p<0.05. (B) Expression levels of 
genes regulating quiescence in HSCs were determined in HSCs isolated from 
BM of WT and S6K1-/- mice. Expression level of each gene was normalized 
with respect to β-actin. Experiment was performed in triplicates. Data are 
expressed as mean ± SEM; *p<0.05. 
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numbers. To determine the effect of S6K1 deficiency on hematopoietic progenitor 
and terminally differentiated cells, we analyzed the frequency and absolute 
number of HPCs along with mature myeloid cells and B lymphocytes in WT and 
S6K1-/- mice. The frequency of GMP was significantly increased in S6K1-/- mice 
while the frequency of MEP was significantly decreased compared to WT 
controls (Figure 7A). The absolute number of CMP and MEP was significantly 
decreased in S6K1-/- mice compared to WT controls, although we did not 
observe any difference in absolute GMP number between two genotypes (Figure 
7B). We observed a significant increase in the frequency of mature myeloid cells 
whereas the frequency of mature B lymphocytes was significantly reduced in 
S6K1-/- compared to WT controls (Figure 8A and B). However only the absolute 
number of B lymphocytes in BM of S6K1-/- mice was significantly reduced 
(Figure 8C). There was no difference in absolute number of mature myeloid cells 
between S6K1-/- mice and WT controls.  
The decrease in BM MNC number in S6K1-/- mice is cell intrinsic: 
Previous studies have shown that S6K1-/- mice have reduced body size 
compared to WT mice (Pende et al., 2004; Selman et al., 2009). To determine 
whether the reduced BM cellularity in S6K1-/- mice is due to deficiency of S6K1 
in BM microenvironment, we transplanted lethally irradiated WT and S6K1-/- 
mice with WT BM MNCs (Figure 9A). We analyzed the absolute number of BM 
MNCs at 16 weeks following transplant. We found that there were no significant 
differences in the BM MNC numbers between two groups of WT BM MNC 
recipients (Figure 9B). To further determine whether the decrease in the BM 
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Figure 7: S6K1-/- mice have altered HPC population in bone marrow. 
(A) Quantitative representation of frequency of CMP, GMP and MEP in BM of 
WT and S6K1-/- mice. n=4-5 in each group. Data are expressed as mean ± SEM; 
*p<0.05. (B) Absolute numbers of CMP, GMP and MEP in two femurs, two tibias, 
and two iliac crests of WT and S6K1-/- mice; n=4-5 mice in each group. 
Data are expressed as mean ± SEM; *p<0.05. 
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Figure 8: S6K1-/- mice have altered mature hematopoietic population in 
bone marrow. 
(A) Representative dot plot of mature myeloid cells (Gr1+ Mac1+) and B
lymphocytes (B220+ CD19+) in BM of WT and S6K1-/- mice. (B) Frequency of 
mature myeloid cells and B lymphocytes in BM of WT and S6K1-/- mice. (C) 
Absolute number of mature myeloid cells and B lymphocytes in two femurs, 
two tibias, and two iliac crests of WT and S6K1-/- mice; n=4-5 mice in each 
group. Data are expressed as mean ± SEM; *p<0.05. 
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cellularity was cell intrinsic, we transplanted lethally irradiated WT mice with 
either WT or S6K1-/- BM MNCs (Figure 10A). We analyzed the absolute number 
of BM MNCs at 16 weeks following transplant. We found that WT recipients of 
S6K1-/- BM MNCs showed significant reduction in BM MNCs compared to 
recipients of WT BM MNCs (Figure 10B). Taken together, these data suggest 
that the decreased number of BM MNCs seen in S6K1-/- mice is cell-intrinsic, 
and not dependent on the expression of S6K1 in the BM microenvironment. 
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Figure 9: The decrease in BM MNCs in S6K1-/- mice is not 
microenvironment dependent. 
(A) Model of transplantation assay to determine the effect of S6K1 deficiency in
BM microenvironment on absolute number of BM MNCs. BM MNCs were 
isolated from WT mice and transplanted into lethally irradiated WT and S6K1-/- 
mice. BM MNC number was determined at 16 weeks post-transplant. (B) 
Absolute number of BM MNCs isolated from two femurs, two tibias, and two 
iliac crests of transplant recipients at 16 weeks post-transplant. Data are 
expressed as mean ± SEM; n=4-5 mice in each group.  
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Figure 10: The decrease in BM MNCs in S6K1-/- mice is cell-intrinsic. 
(A) Model of transplantation assay to determine the effect of S6K1 deficiency in
HSCs on absolute number of BM MNCs. BM MNCs were isolated from WT and 
S6K1-/- mice and transplanted into lethally irradiated WT mice. BM MNC number 
was determined at16 weeks post-transplant. (B) Absolute number of BM MNCs 
isolated from two femurs, two tibias, and two iliac crests of transplant recipients 
in (A) at 16 weeks post-transplant. n=4-5 mice in each group. Data are 
expressed as mean ± SEM; *p<0.05.  
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Discussion: 
The role of mTORC1 activation on steady state hematopoiesis has been 
well characterized (Guo et al., 2013; Juntilla et al., 2010; Magee et al., 2012). 
However, following activation of mTORC1, 4E-BP1 is inactivated and S6K1 is 
activated. Downstream of mTORC1 how these two molecules regulate steady 
state hematopoiesis has not been explored. We found that S6K1 is expressed in 
all the hematopoietic subsets in mice, including HSCs and HPCs. However, the 
expression level of S6K1 is significantly elevated in GMPs and downregulated in 
mature myeloid cells relative to HSCs (Table 3). Interestingly, in S6K1-/- mice, 
the frequency of GMP and mature myeloid cells were both upregulated. These 
data suggest that S6K1 might play a role in differentiation and maturation of 
myeloid cells. In mTOR-/- mice, GMP frequency was also elevated compared to 
WT. Along with our data, it can be concluded that S6K1 negatively regulates 
GMP frequency in hematopoietic compartment. Although S6K1 is expression is 
relatively low in mature myeloid cells compared to HSCs, our data suggests that 
S6K1 is a negative regulator of maturation of myeloid cells. However, this study 
has not assessed whether the increase in GMP frequency in S6K1-/- mice 
corresponds to an increase in functional potential or not. Further studies are 
required to determine the effect of S6K1 deficiency on the functional potential of 
GMPs. In vitro CFU assay with sorted GMP population from WT and S6K1-/- 
mice could further elucidate the role of S6K1 on the functional ability of GMPs. 
Our data establishes S6K1 as critical regulator of absolute number of 
hematopoietic cells. These findings also corroborate previous studies where loss 
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Table 3: Effect of S6K1 deficiency on different hematopoietic subsets in 
    bone marrow compared to WT controls. 
Population Frequency Absolute number 
HSC No change Decreased 
MPP Decreased Decreased 
CMP No change Decreased 
GMP Increased No change 
MEP Decreased Decreased 
Gr1+Mac1+ Increased No change 
B220+CD19+ Decreased Decreased 
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of expression of upstream effectors of S6K1 results in reduced hematopoietic 
cellularity in fetal liver and bone marrow. We also provide evidence that the 
reduced cellularity in S6K1-/- mice is not because of deficiency of S6K1 in 
hematopoietic niche. Our findings are in line with study with mTOR-/- mice. 
mTOR-/- mice have reduced number of absolute hematopoietic cells despite 
having less quiescent HSC/Ps (Guo et al., 2013). Further studies are required to 
determine the exact mechanism underlying reduced cellularity in S6K1-/- mice. 
S6K1 could also regulate HSC/P number by also regulating glycolysis. S6K1 has 
been shown to be a positive regulator of glycolysis in hematopoietic cells. 
Recently Takubo et al. had shown that regulation of glucose metabolism is 
critical for HSC functions (Takubo et al., 2013). HSCs deficient in PDK2 and 
PDK4 have reduced glucose metabolism. Mice transplanted with PDK2 and 
PDK4 HSCs have reduced BM MNCs (Takubo et al., 2013). A study by Liu et al. 
had shown that PDK4 is an activator of mTORC1 (Liu et al., 2014b). 
Overexpression of PDK4 upregulates mTORC1 activity in murine fibroblasts. It is 
probable that in S6K1-/- HSCs PDK4 mediated glycolysis has been 
downregulated, which resulted in reduced number of hematopoietic cells in BM. 
Further studies are required to determine if S6K1 deficiency affects steady state 
hematopoiesis by altering their metabolic profile. 
In our studies, we observed reduced quiescence in S6K1-/- HSCs as there 
was a decrease in number of HSCs in G0 phase of cell cycle compared to WT 
controls. In a previous study, HSCs deficient in mTOR, an activator of S6K1 
activity, showed reduced quiescence in HSCs (Guo et al., 2013). Decrease in 
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quiescence has been associated with functional defects and exhaustion of HSCs. 
One of the key regulator of HSC quiescence is p21. P21 is a member of wild-type 
p53-activated fragment (WAF1), and Cdk-interacting protein (Cip1) family of 
protein (Harper et al., 1993) and acts as a cyclin dependent kinase (CDK) 
inhibitor (Brugarolas et al., 1998; Brugarolas et al., 1999). E2 factor (E2F) family 
of transcription factors are positive regulators of genes required for cell cycle 
progression into and through S phase (Johnson et al., 1993; Lukas et al., 1996; 
Qin et al., 1994). E2Fs are negatively regulated by p107 and p130, two members 
of retinoblastoma (Rb) family (Woo et al., 1997). CDK2 phosphorylates Rb 
proteins and promotes E2F-dependent gene transcription (Akiyama et al., 1992; 
Woo et al., 1997). P21 binds to CDK2 and disrupts the interaction between CDK 
and Rb proteins (Shiyanov et al., 1996; Zhu et al., 1995). This disruption in 
binding with Rb proteins inhibits CDK2 activity, thus resulting in inhibition of E2F-
dependent gene transcription (Brugarolas et al., 1999; Shiyanov et al., 1996). 
CDK2–cyclin A interaction is required for progression through S and G2 phase 
(Gu et al., 1992; Hu et al., 2001). P21 inhibits the kinase activity of CDK2 thus 
inhibiting cell cycle progression. Furthermore, p21 has also been shown to be an 
inhibitor of the kinase activity of CDK1, which results in inhibition of cell cycle 
progression through G2 and G2/M phase (Satyanarayana et al., 2008). P21 can 
also associate with E2F1 directly and suppress cellular growth (Dimri et al., 
1996). In response to notch1 activation, p21 inhibits E2F1-dependent Wnt4 
expression (Devgan et al., 2005). P21 has also been demonstrated as both 
necessary and sufficient to mediate p53-dependent repression of genes that 
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promotes cell cycle progression (Gottifredi et al., 2001; Lohr et al., 2003; Shats et 
al., 2004). P21-/- HSCs undergo increased cycling and exhaust upon serial 
transplantation (Cheng et al., 2000). We show that S6K1-/- HSCs have reduced 
p21 expression level compared to controls. Thus, S6K1-/- HSCs could be less 
quiescent due to decrease in p21 expression. However, further studies are 
required to determine the exact mechanism of how S6K1 regulates p21 
expression in HSCs. 
In summary, we have established the role of S6K1 in steady state 
hematopoiesis. We have demonstrated that S6K1 is expressed in HSCs and 
deficiency of S6K1 results in reduced HSC number (Table 3) as well as a 
decrease in overall HSC/P number. Deficiency of S6K1 results in altered HPC 
and mature effector cells in BM (Table 3). Moreover, we also provide evidence 
that S6K1 is a positive regulator of HSC quiescence. We also provide evidence 
suggesting that S6K1 is a positive regulator of p21 expression in HSCs.  
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Chapter 4: Role of S6K1 in stress hematopoiesis 
Introduction: 
Following exposure to effectors that induce cellular stress, cells respond in 
multiple ways in order to defend against the stress as well as to recover following 
the stress (Kultz, 2005). The responses include activation of pro-survival 
pathways and initiating programmed cell death to eliminate damaged cells. 
Previous studies have established S6K1 as a critical regulator of cellular 
responses to stress. Treatment with doxorubicin, a chemotherapeutic agent, 
upregulates S6K1 phosphorylation in mouse embryonic fibroblasts in a p38α  
MAPK dependent manner (Lai et al., 2010). Activated S6K1 inhibits Mdm2 –
mediated ubiquitination and degradation, which results in increased apoptosis in 
cells following Doxorubicin treatment (Lai et al., 2010).  
In another model of cellular stress, free fatty acids (FFA) induce 
endoplasmic reticulum (ER) stress in hepatocytes in a S6K1-dependent manner 
(Pardo et al., 2015). Inhibition of S6K1 activity results in reduced FFA induced 
ER stress in murine hepatocytes (Pardo et al., 2015). A recent study showed that 
the response to ER stress is critical for HSC function. In hematopoietic system, 
5-FU has been used extensively to study stress hematopoiesis. In HSC/Ps, 5-FU
treatment results in increased S6K1 activity (Basu, 2014). Peroxisome-
proliferator-activated-receptor γ coactivator 1 beta (PGC1β) is required for an 
efficient ER stress response in mouse brain in response to high fat diet (HFD). 
Deficiency of PGC1β results in apoptosis of neurons following administration of 
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HFD. In PGC1β deficient neurons, reduced stress response is associated with 
reduced mTORC1 activity. PGC1α is another member of PGC family and is 
expressed in HSCs. In PGC1α-/- mice, S6K1 phosphorylation level, 
mitochondrial membrane potential and ROS level are elevated in HSC/Ps 
following 5-FU treatment (Basu, 2014). Rapamycin treatment reduces S6K1 
phosphorylation in 5-FU treated PGC1α-/- HSCs, which resulted in reduced 
ROS level and mitochondrial membrane potential (Basu, 2014). Overall, these 
data suggest that S6K1 plays a critical role in stress response in different cells. 
However, the exact role of S6K1 in the regeneration of HSCs following 
myeloablative stress is not well defined. 
In this chapter, we show that following myeloablative stress, S6K1 
deficient HSC/Ps increase in frequency. We also show that the increased 
frequency of HSC/P is in part due to increase in cell cycle of S6K1 deficient 
HSC/Ps. Competitive transplantation using 5-FU treated HSC/Ps showed 
reduced functional potential of S6K1-/- HSC/Ps compared to controls following 
exposure to chemotherapeutic agent. We also demonstrate that myeloablative 
stress results in reduced quiescence of S6K1 deficient HSC/Ps that renders them 
susceptible to repeated myeloablative stress.  
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Results: 
S6K1 regulates recovery of HSC/Ps following myelotoxic stress: 
Following 5-FU injection, cycling HSCs and HPCs acquire DNA damage 
and undergo apoptosis. Quiescent HSCs undergo self-renewal and differentiation 
for recovery of the mature hematopoietic cells as well as to replenish the HSC 
pool (Harrison and Lerner, 1991; Venezia et al., 2004). To determine the role of 
S6K1 in the recovery of hematopoietic system following myelotoxic stress, we 
injected WT and S6K1-/- mice with a single dose of 5-FU. We monitored the 
recovery of peripheral blood WBCs at different time points post 5-FU treatment. 
No significant change in WBC counts in the peripheral blood of S6K1-/- mice 
were seen compared to WT controls after 5-FU treatment (Figure 11A).  
To determine the effect of 5-FU on S6K1 deficient BM HSC/Ps, we 
determined the bone marrow cellularity of WT and S6K1-/- mice after 5-FU 
injection at different time points (Figure 11B). As described in the previous 
chapter, there was a significant reduction in the BM MNC number of S6K1-/- 
mice at day 0 (Figure 11B). However, the difference in BM cellularity did not 
persist on day 6 and day 9 post 5-FU treatment. We observed a significant 
difference in the BM cellularity on day 15 post 5-FU injection (Figure 11B). In the 
hematopoietic hierarchy, LSK cells are a heterogeneous population that are 
enriched in HSCs having long-term repopulating potential as well as MPPs 
(Uchida et al., 1994). We analyzed the LSK frequency in BM of WT and S6K1-/- 
mice at different time point after 5-FU treatment. In the BM of S6K1-/- mice, there 
was a significant increase in LSK frequency on day 9 after 5-FU treatment 
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Figure 11: Effect of loss of expression of S6K1 on recovery of 
hematopoietic system following myeloablative stress. 
(A) Quantitative representation of WBC count in peripheral blood of WT and
S6K1-/- mice at different time points following 5-FU treatment. Data are 
expressed as mean ± SEM; n=4-12 mice in each genotype. (B) Quantitative 
representation of BM MNC number isolated from two femurs, two tibias, and 
two iliac crests of WT and S6K1-/- mice at different time points following 5-FU 
treatment; n=12-19 mice in each group. Difference between the group means 
was analyzed by one-way ANOVA with Bonferroni post-hoc analysis. Data 
are expressed as mean ± SEM; *p<0.05. 
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Figure 12: Increased frequency of LSK cells in BM of S6K1-/- mice after 5-
FU treatment. 
(A) Representative dot plot of LSK cells in BM of WT and S6K1-/- mice after 9
day following a single dose of 5-FU. Cells are gated on linage negative 
population. (B) Quantitative representation of absolute number of LSK cells in 
the BM of WT and S6K1-/- mice at 9 days after 5-FU treatment; n=16-19 mice in 
each group. Data are expressed as mean ± SEM. (C) Quantitative 
representation of frequency of LSK cells in the BM of WT and S6K1-/- mice at 
different time points following a single dose of 5-FU; n=8-19 mice in each group 
in each time point. Difference between the group means was analyzed by one-
way ANOVA with Bonferroni post-hoc analysis. Data are expressed as mean ± 
SEM; *p<0.05. 
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(Figure 12A and C). However, there was no difference in LSK frequency between 
the two groups at steady state and on day 6 and day 15 after 5-FU treatment 
(Figure 12C). Furthermore, there was no change in the absolute BM LSK number 
in S6K1-/- mice compared to WT controls after day 9 following 5-FU injection 
(Figure 12B). These data suggest that S6K1 deficiency results in a transient 
increase in the frequency of LSK cells during the recovery of the hematopoietic 
system following myelotoxic stress. 
S6K1 deficiency results in increased cycling of HSC/Ps following 
myeloablative stress: 
5′-bromo-2′-deoxyuridine (BrdU) is a DNA analog that is incorporated into 
the DNA of proliferating cells (Nowakowski et al., 1989). BrdU substitutes for 
thymidine residues within DNA during replication (Nowakowski et al., 1989). 
Analysis of BrdU incorporation into the DNA of replicating cells within a defined 
period can reveal what proportion of cells have undergone cell cycle in that 
period. BrdU incorporation over a short-term period has been previously used to 
identify the cycling status of HSCs (Cheshier et al., 1999; Fleming et al., 1993; 
Goodell et al., 1996). We hypothesized that the increase in frequency of LSK cells 
in the bone marrow of S6K1-/- mice on day 9 following 5-FU treatment could be 
due to increased cycling of the LSK population. We injected WT and S6K1-/- mice 
with BrdU on day 8 post 5-FU injection. After 16 hours, mice were euthanized, BM 
MNCs were isolated and stained for LSK cells. After staining, cells were washed 
and BrdU incorporation assay was performed. LSK cells in S6K1-/- mice 
displayed a significant increase in BrdU positive cells compared to WT controls 
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Figure 13: S6K1-/- HSC/Ps undergo increased cycling following 5-FU 
treatment. 
(A) Representative dot plot of BrdU+ LSK cells in BM of WT and S6K1-/- mice
after 9 day following a single dose of 5-FU. Cells are gated on LSK population.  
(B) Quantitative representation of frequency of BrdU+ LSK cells in the BM of
WT and S6K1-/- mice after 9 day following 5-FU treatment; n=3-4 mice in each 
group. Data are expressed as mean ± SEM; *p<0.05. 
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Figure 14: Cyclin G1 expression is increased in S6K1-/- LSK cells following 
5-FU treatment.
Expression level of genes regulating cell cycle in BM LSK cells isolated from 
WT and S6K1-/- mice 9 days following a single dose of 5-FU. Expression level 
in each gene was normalized to β  -actin expression and expressed as values 
relative to WT. Experiment was performed in quadruplicates. Data are 
expressed as mean ± SD; *p<0.05. 
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(Figure 13A, B). This result suggests that following myelotoxic treatment, the 
HSC/P enriched population within the bone marrow undergoes increased cycling 
in the absence of S6K1. We next analyzed genes involved in regulating different 
phases of cell cycle. We isolated BM MNCs from WT and S6K1-/- mice on day 9 
after 5-FU treatment and sorted LSK cells using FACS. We analyzed expression 
level of genes by qRT-PCR. Expression level of Cyclin G1 was increased in the 
LSK population derived from S6K1-/- mice compared to WT control (Figure 14). 
This suggests that Cyclin G1 might contribute to the increased cycling of LSK 
cells in absence of S6K1 following 5-FU treatment. 
S6K1-/- mice are susceptible to repeated myeloablative stress: 
Quiescent HSCs within the bone marrow are protected from myeloablative 
treatment because of their low cell cycle status. Increase in cell cycle progression 
renders HSCs more susceptible to myeloablative stress (Miyamoto et al., 2007). 
Since we observed increased cycling of S6K1-/- LSK cells following myelotoxic 
stress, we hypothesized that loss of S6K1 expression in HSCs will result in 
increased susceptibility to such stress. For our studies, we have used a previously 
described model of repeated myeloablative stress (Miyamoto et al., 2007). WT and 
S6K1-/- mice were injected with weekly doses of 5-FU (Figure 15A). As 5-FU 
ablates the proliferating HSCs, quiescent HSCs are forced to proliferate and 
reconstitute the hematopoietic system. However, due to repeated doses of 5-FU, 
the quiescent HSCs that started proliferating after previous dose of 5-FU is 
depleted and a new pool of quiescent HSCs is required to reconstitute the 
hematopoietic system and mice with reduced number of quiescent HSCs succumb 
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Figure 15: S6K1 deficiency renders mice susceptible to repeated 
myelotoxic stress. 
(A) Model of repeated myeloablative stress using 5-FU. WT and S6K1-/- mice
were treated with 5-FU at an interval of 7 days and the mice were monitored for 
survival. (B) Kaplan-Meier survival curve of WT and S6K1-/- mice after repeated 
doses of 5-FU. Statistical significance between the survival of two groups were 
analyzed by the log-rank (Mantel-Cox) test; n=11 WT & 15 S6K1-/-;*p<0.01. 
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earlier to repeated myelotoxic stress due to hematopoietic exhaustion. Following 
weekly doses of 5-FU, S6K1-/- mice succumbed to death significantly earlier 
compared to WT mice. The median survival time of S6K1-/- mice was 17 days 
while the median survival time for WT controls was 21 days (Figure 15B). This 
suggests that S6K1 deficiency results in loss of quiescence in HSCs leading to 
hematopoietic exhaustion following repeated myelotoxic stress. 
S6K1 deficient HSC/Ps have reduced engraftment potential following  
myelotoxic stress: 
Previous studies have shown that in the BM of WT mice, phenotypically 
defined HSCs reach maximum frequency on day 6 post 5-FU administration 
(Venezia et al., 2004). To determine whether 5-FU administration affect the 
functional ability of S6K1 deficient HSCs, we performed CRA with cells derived 
from WT and S6K1-/- mice after 6 days following 5-FU injection. We mixed the test 
cells with competing Boy/J BM MNCs at two different doses and transplanted them 
into lethally irradiated mice. When mice were transplanted with cells at a ratio of 
1:8 (test: competitor), we observed a significant decrease in donor-derived cells in 
the peripheral blood of recipients of S6K1-/- BM MNCs (Figure 16A). The 
decrease in the engraftment persisted until 16 weeks following transplant. 
However, when recipients were transplanted with 1:4 (test: competitor) cell 
dilution, there were no difference in the contribution of donor-derived cells in the 
peripheral blood of recipients of S6K1-/- BM MNCs (Figure 16B). These results 
suggest that following genotoxic stress, S6K1 protects the functional potential of 
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Figure 16: S6K1-/- HSCs have reduced engraftment after exposure to 
chemotherapeutic agents. 
(A) WT and S6K1-/- mice were treated with a single dose of 5-FU. On 6th day
following 5-FU treatment, BM MNCs were isolated, mixed with competitor BM 
MNCs isolated from Boy/J mice and transplanted into lethally irradiated hosts. 
Donor-derived (CD45.2+) cells in peripheral blood of recipients of cells in ratio of 
1:8 (test:competitor) was determined at different time points following 
transplantation. (B) Donor-derived (CD45.2+) cells in peripheral blood of 
recipients cells in ratio of 1:4 (test:competitor) was determined at different time 
points following transplantation. n=3-4 mice in each recipient group. Data are 
expressed as mean ± SEM. Difference between the group means was analyzed 
by one-way ANOVA with Bonferroni post-hoc analysis; *p<0.05. 
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HSC/Ps and the deficiency of S6K1 results in reduced engraftment of HSC/Ps 
following 5-FU treatment. 
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Discussion: 
Chemotherapeutic agents like 5-FU cause DNA damage and induces 
apoptosis in proliferating HSCs. Quiescent HSCs undergo rapid proliferation and 
rapid cycling during the recovery of hematopoietic system. Previous studies 
found S6K1 to function as a repressor of cell cycle progression (Henriques et al., 
2013). We found that HSC enriched population in the bone marrow undergo 
increased cycling following 5-FU treatment. Our data suggests that S6K1 is 
required for HSCs to re-enter their quiescent state after they have undergone 
proliferation following myeloablative stress. Our studies find that S6K1-/- HSC/Ps 
increase in frequency on 9th day post 5-FU treatment. Our data revealed no 
significant difference on day 6 and day 15 post 5-FU treatment on HSC/P 
frequency between S6K1-/- and control HSC/Ps. S6K1-/- mice display similar 
hematopoietic response like CD81-/- mice in response to stress. Lin et al. had 
shown that in HSCs, CD81 is required for re-entering quiescence following 5-FU 
induced proliferation (Lin et al., 2011). Similar to S6K1-/- mice, CD81-/- mice had 
increased HSC frequency at a single time point following myeloablative stress. 
On day 8 following myeloablative stress, the HSC frequency in CD81-/- mice was 
increased. However, there were no significant changes in the frequency of CD81-
/- HSCs on day 4, day 7 and day 12 post 5-FU treatment. Our studies observed 
an increase in S6K1-/- HSC-enriched population at similar time point following 
myeloablative stress when compared to CD81-/- HSCs. It is possible that S6K1 
regulates the return of quiescence state of HSCs in a similar mechanism like 
CD81, which causes increase in LSK frequency at a single time point after 
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myeloablative stress. CD81 inhibits Akt activity in HSCs, which results in nuclear 
translocation of Foxo1a (Lin et al., 2011). S6K1 has been revealed as negative 
regulator of Akt activation. S6K1 acts in a negative feedback loop to repress 
mTORC2-dependent and IRS-1 dependent Akt activation (Um et al., 2004. Um et 
al. have shown that  in S6K1-/- mice maintained on high-fat diet, insulin-induced 
Akt activity is significantly upregulated compared to controls (Um et al., 2004). 
Additionally, S6K1 mediated phosphorylation of Rictor, a component of 
mTORC2, inhibits mTORC2 and Akt activation (Julien et al., 2010; Treins et al., 
2010). It is possible that in the absence of S6K1, Akt activity is upregulated in 
HSCs following myeloablative stress, which might have prevented S6K1-/- HSCs 
from re-entering quiescence by regulating Foxo1a activity. To further elucidate 
the signaling mechanism, expression and activation level of Akt, CD81 and 
Foxo1A is required in S6K1-/- HSCs following myeloblative stress. 
Autophagy has also been identified as an important factor in response to 
stress induced by chemotherapeutic agents. Li et al. showed that inhibition of 
autophagy increases 5-FU induced apoptosis in human colon cancer cells (Li et 
al., 2010). A recent study by Hac et al. showed that S6K1 does not play a role in 
autophagy under normal growth condition (Hac et al., 2015). However, under 
stress conditions, S6K1 activity is required for digestion of autophagosome 
interior by lysosomal proteases, which is the final stage of autophagy (Hac et al., 
2015). Autophagy activity has been shown to be active in HSCs, but not in 
committed myeloid progenitors, which suggests that HSCs require the autophagy 
protective mechanism. In our model, S6K1 deficiency could result in reduced 
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autophagy in HSCs and along with loss of quiescence, could contribute to 
increased susceptibility of S6K1-/- mice to repeated myeloablative stress. S6K1-
/- mice also mirrors the phenotype of p21-/- mice in response to stress. P21-/- 
mice survive significantly shorter time compared to WT mice when exposed to 
repeated myeloablative stress (Cheng et al., 2000). In previous chapter, we have 
shown that in steady-state, p21 expression to be significantly reduced in S6K1-/- 
HSCs compared to controls. The increased susceptibility of S6K1-/- mice to 
myeloablative stress could be due to reduced p21 levels in HSCs. We also 
provide evidence to suggest that deficiency of S6K1 results in reduced 
engraftment of HSC/Ps following myeloablative stress. Quiescent HSCs have 
better homing and repopulating ability compared to actively cycling HSCs 
(Orschell-Traycoff et al., 2000). Since S6K1 deficiency results in increased 
cycling of HSC/Ps following myeloablative stress, this could contribute to their 
reduced engraftment in lethally irradiated recipients. However, we did not 
observe a statistically significant difference when we used a lower dilution for the 
transplantation studies. It could be possible that at a lower dilution, the number of 
functional HSC/Ps in S6K1-/- mice is higher to overcome the competitive 
disadvantage. 
In summary, we have established S6K1 as a critical regulator of recovery 
of the hematopoietic system following myeloablative stress and regulator of 
quiescence of HSCs. Loss of S6K1 expression in HSC/Ps results in increased 
cycling following myeloablative stress and S6K1 protects HSCs from repeated 
myeloablative stress. Additionally, we have also provided evidence that S6K1 
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deficiency causes reduced engraftment of HSC/Ps following myeloablative 
stress. 
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Chapter 5: Modulation of S6K1 expression results in 
reduced self-renewal of HSCs 
Introduction: 
Previous studies have established a role for the PI3K-mTORC1 pathway 
in regulating the function of HSCs. Deficiency of p85α subunit of PI3K complex in 
fetal liver HSCs results in reduced long-term engraftment of HSCs when 
transplanted into lethally irradiated recipients (Haneline et al., 2006). 
Furthermore, differentiation of HSCs into myeloid and lymphoid lineages in 
peripheral blood of transplanted mice was also reduced in comparison to controls 
(Haneline et al., 2006). Deficiency of Akt1 and Akt2 in fetal liver HSCs as well as 
in adult young HSCs also results in reduced engraftment in peripheral blood of 
recipients following serial transplantation (Juntilla et al., 2010). Myeloid and 
lymphoid lineages were reduced in Akt1 and Akt2 deficient HSC recipients 
compared to control (Juntilla et al., 2010). mTOR deficient HSCs have 
significantly reduced engraftment potential in lethally irradiated transplant 
recipients (Guo et al., 2013). In contrast, pharmacological inhibition of mTORC1 
by rapamycin has yielded opposite results compared to genetic approaches. 
Inhibition of mTORC1 activity in old HSCs by administering rapamycin results in 
increased long-term engraftment of HSCs (Chen et al., 2009). Treatment of ex-
vivo expanded HSCs by rapamycin results in increase in long-term engraftment 
of HSCs (Luo et al., 2014). 
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Figure 17: Schematic model of Akt-mTORC1 signaling in HSCs. 
A schematic of Akt-mTORC1 signaling pathway in HSCs based on curren 
literature. Following phosphorylation, activated Akt phosphorylates and inhibits 
tuberous Sclerosis 2 (TSC2)-mediated inhibition of Rheb. Activated Rheb 
subsequently phosphorylates and activates mTORC1. Activated mTORC1 
phosphorylates the translational regulators eukaryotic translation initiation factor 
4E (eIF4E)-binding protein 1 (4E-BP1) and ribosomal protein S6 kinase 1 
(S6K1). Foxo family of transcription factors translocate to nucleus and regulate 
gene expression. Akt phosphorylates Foxo group of transcription factors and 
inhibits their nuclear translocations by sequestering them within the cytoplasm. 
On the other hand, Itpkb acts as an inhibitor of Akt activity and subsequently 
represses mTORC1 activation. 
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Interestingly, hyperactivation of mTORC1, which is the major activator of 
S6K1, also affect HSC function. Increase in Akt activity, a positive regulator of 
S6K1 (Figure 17), causes dysfunction in HSCs and mice develops 
myeloproliferative disorders as well as T-cell lymphoma (Kharas et al., 2010). 
HSCs bearing constitutively active Akt also display reduced engraftment 
following transplantation (Kharas et al., 2010). Inositol-trisphosphate 3-kinases 
(Itpk) phosphorylate IP4 that results in subsequent inhibition of Akt activity (Jia et 
al., 2007). Among three isoforms of Itpk, HSCs express only Itpkb isoform and 
deficiency of Itpkb results in increased absolute number of LT-HSCs and MPPs 
within the bone marrow (Siegemund et al., 2015). The increase in LT-HSC 
number is associated with a subsequent decrease in quiescent HSCs in Itpkb-/- 
mice (Siegemund et al., 2015). Itpkb deficiency also results in deficiency of long-
term self-renewal ability of HSCs (Siegemund et al., 2015). Itpkb-/- mice develop 
hematopoietic disorders with progressive ageing, which includes reduced LT-
HSCs, MPPS and HPCs in bone marrow and succumb to anemia (Siegemund et 
al., 2015). Itpkb deficient LT-HSCs display increased cytokine induced Akt 
activation. Rapamycin treatment reduces hyperproliferation of Itpkb-/- LT-HSCs 
as well as decreases mTORC1 activity (Siegemund et al., 2015). These data 
suggest that Itpkb is a negative regulator of Akt-mTORC1 activity in HSCs 
(Figure 17). 
 In vivo inflammation also results in increased mTORC1-S6K1 activity in 
HSCs, which causes reduced bone marrow cellularity and reduction in the 
functional potential of HSCs (Chen et al., 2010). Treatment with rapamycin can 
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revert the defects in HSCs caused by inflammation, which suggests that 
hyperactivation of mTORC1 negatively regulates HSC function (Chen et al., 
2010). IFNα, a mediator of inflammation, causes loss of quiescence followed by 
increased cycling of HSCs (Essers et al., 2009). IFNα also reduces PTEN 
expression in HSCs along with an increase in Akt phosphorylation. PTEN, a 
negative regulator of mTORC1-S6K1 activity (Figure 17), itself is a critical 
mediator of HSC function. Deletion of PTEN results in reduced engraftment of 
HSCs and expansion of myeloid population following transplant (Yilmaz et al., 
2006b; Zhang et al., 2006). Interestingly PTEN differentially regulates functional 
potential of neonatal and adult HSCs. Neonatal HSCs deficient in PTEN show 
multilineage differentiation potential from 16 to 24 weeks post-transplant (Magee 
et al., 2012). However, their reconstitution capability diminishes after 24 weeks 
(Magee et al., 2012). In contrast, adult HSCs fail to reconstitute hematopoiesis 
up to 16 weeks post-transplant (Magee et al., 2012). The differential functional 
capability could be attributed to the maturation of neonatal HSCs to adult HSCs 
over the period. Similarly, in adult HSCs, PTEN deletion results in activation of 
PI3K-mTORC1 pathway but not in neonatal HSCs. In PTEN-deficient adult HSCs 
increased mTORC2 activity results in increased Akt activation (Figure 17) 
(Magee et al., 2012). Deletion of Rictor, a component of mTORC2, results in 
restoration of long-term functional potential of PTEN deficient HSCs (Magee et 
al., 2012).  
The Foxo group of transcription factors regulate transcription of genes 
involved in cell-cycle arrest, apoptosis, and reactive oxygen species (ROS) 
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detoxification. Activated Akt phosphorylates Foxo group of proteins thus 
facilitating their removal from the nucleus and suppressing Foxo dependent gene 
transcription (Figure 17). PTEN deletion results in activation of Akt and mTORC1 
in adult HSCs but does not alter Foxo1 or Foxo3a expression level nor does it 
affect Foxo3a nuclear localization (Lee et al., 2010). Treatment of HSCs with 
rapamycin also results in increased Akt activation, which suggests that there is a 
negative feedback loop in HSCs that is downstream of mTORC1 (Lee et al., 
2010). Downstream of PTEN, constitutive activation of Akt results in increased 
phenotypic expansion of HSCs as a consequence of increased cycling, which 
gradually results in apoptosis of HSCs and reduced engraftment ability (Kharas 
et al., 2010).  Mice bearing constitutively active Akt in HSCs develop MPD, AML 
and T cell lymphoma along with an accumulation of immature myeloid cells in 
bone marrow (Kharas et al., 2010). However, a recent study has shown that 
HSCs and MPPs undergoing cell cycle progression do not require increased Akt 
activation (Magee et al., 2012).  
TSC1 and TSC2 are negative regulators of mTORC1-S6K1 activity and 
TSC1 deletion in HSCs results in increased mTORC1 activity (Chen et al., 2008). 
Conditional deletion of TSC1 in HSCs results in increased cycling and apoptosis 
(Chen et al., 2008). However, the cycling rate of TSC1 deficient HSCs is higher 
compared to their apoptosis rate. Functionally, TSC1 deficient HSCs have 
reduced self-renewal potential. TSC1 deficiency results in increased 
mitochondria biogenesis along with increased ROS production in HSCs. In 
another study, deletion of TSC1 in HSCs also resulted in reduced quiescence 
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and decreased self-renewal potential that was regulated by a mTORC1 
dependent pathway.  
Rheb2 is a direct activator of mTORC1 activity (Figure 17) and 
overexpression of Rheb2 results in hyperactivation of mTORC1 in hematopoietic 
cells (Campbell et al., 2009). Overexpression of Rheb2 in HSCs causes 
phenotypic expansion of HSCs along with a reduction in self-renewal ability 
(Campbell et al., 2009).  
Overall, previous works from different groups involving both deficiency and 
hyperactivity of mTORC1 have demonstrated that maintenance of an optimal 
mTORC1 activity level is key for the HSC function. Modulation of mTORC1 
activity level can result in reduced long-term engraftment and self-renewal of 
HSCs. However, the exact role of S6K1 expression and activity level in regulation 
of HSC function has not been investigated. We hypothesized that as S6K1 is a 
downstream substrate of mTORC1, it acts as a main effector of mTORC1 
signaling in HSCs and HSCs functional ability depend on an optimal level of 
S6K1 activity. 
In this chapter, we show that modulation of S6K1 expression level in 
HSCs results in reduced self-renewal. Our studies demonstrate that deficiency of 
S6K1 results in reduced self-renewal of HSCs. Our studies also reveal that S6K1 
deficiency does not affect differentiation and homing ability of HSCs. We show 
that decreased self-renewal of S6K1 deficient HSCs corresponds to a decrease 
in p21 level. Overexpression of S6K1 in HSCs results in reduced short-term and 
long-term engraftment as well as decreased self-renewal potential. Overall, our 
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studies establish that expression level of S6K1 in HSCs is a key regulator of their 
self-renewal potential. Both deficiency of S6K1 and its overexpression results in 
decreased self-renewal of HSCs. 
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Results: 
S6K1 deficiency does not affect homing, engraftment or multi-lineage 
differentiation of HSCs: 
Given the critical role of upstream effectors of S6K1 in the regulation of 
HSC function, we hypothesized that S6K1 might be a critical regulator of 
engraftment and self-renewal of HSCs. To determine the role of S6K1 on HSC 
function, competitive repopulation assay was performed with MNCs isolated from 
adult WT or S6K1-/- mice (Figure 18). S6K1-/- HSC/Ps showed reduced 
engraftment in the peripheral blood of recipients compared to controls as 
determined by engraftment of CD45.2+ cells in peripheral blood after 5 weeks of 
transplant compared to control group transplanted with WT HSC/Ps. The 
reduced engraftment of S6K1-/- HSC/Ps persisted until week 16 post-transplant 
(Figure 19A and B). However, from week 16 to week 24 post-transplant, there 
were no significant differences between the engraftment of CD45.2+ cells in 
peripheral blood of the recipients of either WT or S6K1-/- HSC/Ps (Figure 19A 
and B).  At 8, 16 and 24 weeks post-transplant, there was no difference in the 
differentiation of S6K1-/- cells into myeloid (Gr1+, Mac1+, Gr1+Mac1+), B cells 
(B220+) and T cells (CD3+) in the peripheral blood of recipients as compared to 
WT controls (Figure 20A and B). The differentiation of WT and S6K1-/- HSC/Ps 
were also similar at 8 weeks 16 weeks and 24 weeks post-transplant (Figure 
20B), which suggests that the decrease in engraftment was not due to reduced 
differentiation of S6K1-/- cells. These results suggest that S6K1 deficiency in 
HSCs does not affect long-term engraftment and differentiation of HSCs in 
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Figure 18: Model of CRA for primary transplant using unfractionated BM 
MNCs. 
Model of CRA for primary transplant using unfractionated BM MNCs. Aseptically 
isolated 5X105 WT or S6K1-/- MNCs (CD45.2+) were mixed with 5X105 MNCs 
isolated from Boy/J mice (CD45.1+) and transplanted into lethally irradiated F1 
recipients. Peripheral blood was obtained from the recipients at different time 
points and analyzed for engraftment of donor-derived cells (CD45.2+) by flow 
cytometry.  
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Figure 19: Effect of loss of expression of S6K1 on engraftment of HSCs in 
primary transplant recipients. 
(A) Representative flow plot of peripheral blood of primary transplant recipients of
either WT or S6K1-/- MNCs at 4 weeks and 24 weeks of transplantation. 
Peripheral blood was obtained from the recipients at different time points and 
analyzed for engraftment of donor-derived cells by flow cytometry. (B) 
Quantitative representation of donor-derived cells in peripheral blood of primary 
transplant recipients of either WT or S6K1-/- MNCs; n=7 mice in each group. 
Data are expressed as mean ± SEM. Difference between the group means was 
analyzed by one-way ANOVA with Bonferroni post-hoc analysis; *p<0.05. 
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Figure 20: S6K1 deficiency does not affect differentiation of HSCs. 
(A) Representative flow plot of donor-derived (CD45.2+) myeloid (Gr1+ Mac1+)
and lymphoid cells (B220+; CD3+) in peripheral blood of primary transplant 
recipients of either WT or S6K1-/- MNCs at 24 weeks post-transplant. Peripheral 
blood was obtained from the primary transplant recipients at 24 weeks post-
transplant and analyzed for engraftment and differentiation of donor-derived cells 
by flow cytometry. (B) Quantitative representation of donor-derived myeloid 
(Gr1+, Mac1+, Gr1+Mac1+) and lymphoid cells in peripheral blood of primary 
transplant recipients of WT or S6K1-/- MNCs at 8, 16 and 24 weeks post-
transplant; n=7 mice in each group. Data are expressed as mean ± SEM. 
Difference between the group means was analyzed by one-way ANOVA with 
Bonferroni post-hoc analysis. 
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primary recipients. Following intravenous transplantation, HSCs have to cross 
blood-bone marrow endothelium barrier in order to engraft into the bone marrow 
compartment (Lapidot et al., 2005). The process, known as homing, is a rapid 
process and the initial event following bone marrow transplant (Lapidot et al., 
2005). Given the importance of homing on engraftment of HSCs, we 
hypothesized that the initial defect in engraftment of S6K1-/- HSCs could be due 
to reduced homing. To test this hypothesis, we performed homing experiments 
with WT and S6K1-/- HSC/Ps. DiD is a lipophilic carbocyanine dye which is 
photostable when incorporated in to the cell membrane and has very low 
cytotoxicity (Sipkins et al., 2005; Sutton et al., 2008). Following incubation with 
the cells, DiD diffuses laterally through the cellular plasma membrane and stains 
the cell (Sipkins et al., 2005; Sutton et al., 2008). BM MNCs were isolated from 
WT and S6K1-/- mice and labeled with DiD. We transplanted DiD labelled WT or 
S6K1-/- MNCs into lethally irradiated mice. Deficiency of S6K1 did not affect the 
homing of DiD+ LSK cells that are enriched in HSCs (Figure 21A and B), which 
suggests that S6K1 deficiency does not affect homing of HSCs into bone 
marrow.  
In order to determine whether the defect in short-term engraftment is HSC 
specific or not, we sorted HSCs (CD150+ CD48- LSK), mixed them with syngenic 
competitor bone marrow cells and transplanted into lethally irradiated mice 
(Figure 22). In the primary transplant recipients, there were no differences in the 
engraftment of HSCs in the peripheral blood between the two groups (Figure 23A 
and B). After 24 weeks post-transplant, there were no difference in the 
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Figure 21: S6K1 deficiency does not affect homing of HSCs. 
(A) Representative flow plot (gated on DiD+ Lin- cells) of DiD+ LSK cells in bone
marrow of lethally irradiated hosts transplanted with either WT or S6K1-/- MNCs. 
MNCs isolated from either WT or S6K1-/- mice were labelled with DiD and 1X107
MNCs were injected intravenously into lethally irradiated Boy/J mice. The 
recipients were euthanized after 18 hours and MNCs were isolated. Cells were 
stained with antibodies against lineage markers, Sca1 and c-Kit and acquired 
using FACS. (B) Quantitative representation of DiD+ LSK cells in bone marrow of 
lethally irradiated hosts transplanted with either WT or S6K1-/- MNCs; n=6-7 
mice in each group. Data are expressed as mean ± SEM. 
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Figure 22: Model of CRA for primary transplant using LT-HSCs. 
Model of CRA for primary transplant using LT-HSCs. 250 WT or S6K1-/- LT-
HSCs (CD45.2+ CD150+ CD48- LSK) were mixed with 3X105 MNCs isolated 
from Boy/J mice (CD45.1+) and transplanted into lethally irradiated F1 recipients. 
Peripheral blood was obtained from the recipients at different time points and 
analyzed for engraftment of donor-derived cells by flow cytometry.  
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Figure 23: Loss of expression of S6K1 does not affect engraftment of HSCs 
in primary transplant recipients. 
(A) Representative flow plot of peripheral blood of primary transplant recipients of
either WT or S6K1-/- MNCs after 4 weeks and 24 weeks of transplantation. 250 
WT or S6K1-/- LT-HSCs (CD45.2+ CD150+ CD48- LSK) were mixed with 3X105 
MNCs isolated from Boy/J mice (CD45.1+) and transplanted into lethally 
irradiated F1 recipients. Peripheral blood was obtained from the recipients at 
different time points and analyzed for engraftment of donor-derived cells by flow 
cytometry. (B) Quantitative representation of donor-derived cells in peripheral 
blood of primary transplant recipients of either WT or S6K1-/- LT-HSCs; n=6-7 
mice in each group. Data are expressed as mean ± SEM. Difference between 
the group means was analyzed by one-way ANOVA with Bonferroni post-hoc 
analysis. 
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differentiation of S6K1-/- cells into myeloid (Gr1+-Mac1+), B cells (B220+) and T 
cells (CD3+) in the peripheral blood of recipients (Figure 24A and B). Overall, 
these data suggest that S6K1 deficiency in HSCs does not affect long-term 
engraftment, homing and differentiation of HSCs.  
S6K1 deficiency results in reduced self-renewal of HSCs: 
The functional activity of HSCs in vivo can be determined by their ability to 
sustain hematopoiesis through serial transplantation (Purton and Scadden, 
2007). To determine whether S6K1 is a regulator of self-renewal of HSCs, we 
performed secondary transplant with cells derived from primary transplant 
recipients. At 24 weeks after primary transplant, we isolated MNCs from WT or 
KO primary recipients and transplanted them into lethally irradiated recipients 
(Figure 25). We observed a significant reduction in the engraftment of S6K1-/- 
recipients in the peripheral blood of recipients from week 4 to week 16 post-
transplant (Figure 26A and B). 
In order to determine whether this defect in engraftment is HSC specific or 
not, we isolated BM MNCs from primary recipients of either WT or S6K1-/- HSCs 
and transplanted them into lethally irradiated recipients (Figure 27). The donor-
derived cells in the peripheral blood of the secondary recipients bearing S6K1-/- 
HSCs was significantly decreased compared to WT controls (Figure 28A and B). 
The difference persisted from week 4 to week 24 post-transplant (Figure 28A and 
B). The engraftment of CD45.2+ cells in the BM of secondary recipients bearing 
S6K1-/- cells was significantly decreased compared to WT controls (Figure 29A 
and B). To determine whether the reduction in engraftment of S6K1-/- HSCs 
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Figure 24: S6K1 deficiency does not affect differentiation of HSCs. 
(A) Representative flow plot of donor-derived (CD45.2+) myeloid (Gr1+ Mac1+)
and lymphoid cells (B220+; CD3+) in peripheral blood of primary transplant 
recipients of either WT or S6K1-/- LT-HSCs after 24 weeks post-transplant. 
Peripheral blood was obtained from the primary transplant recipients after 24 
weeks post-transplant and analyzed for engraftment and differentiation of donor-
derived cells by flow cytometry. (B) Quantitative representation of donor-derived 
myeloid and lymphoid cells in peripheral blood of primary transplant recipients 
of either WT or S6K1-/- LT-HSCs after 24 weeks post-transplant; n=6-7 mice in 
each group. Data are expressed as mean ± SEM. Difference between the group 
means was analyzed by one-way ANOVA with Bonferroni post-hoc analysis. 
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Figure 25: Model of secondary transplant with BM MNCs as primary donor 
cells. 
After 24 weeks of primary transplant, 1X106 MNCs isolated from the recipients of 
either WT or S6K1-/- BM MNCs and transplanted into lethally irradiated F1 
recipients. Peripheral blood was obtained from the secondary recipients at 
different time points and analyzed for engraftment of donor-derived cells by flow 
cytometry.  
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Figure 26: S6K1 deficiency causes reduced self-renewal of HSCs. 
(A) Representative flow plot of peripheral blood of secondary transplant
recipients of either WT or S6K1-/- MNCs after 4 and 16 weeks of transplantation. 
After 24 weeks of primary transplant, 1X106 MNCs were isolated from the 
recipients of either WT or S6K1-/- MNCs and transplanted into lethally irradiated 
F1 recipients. Peripheral blood was obtained from the secondary recipients at 
different time points and analyzed for engraftment of donor-derived cells by flow 
cytometry. (B) Quantitative representation of donor-derived cells in peripheral 
blood of secondary transplant recipients with cells derived from primary 
transplant recipients of either WT or S6K1-/- MNCs; n=6-7 mice in each group. 
Data are expressed as mean ± SEM. Difference between the group means was 
analyzed by one-way ANOVA with Bonferroni post-hoc analysis; *p<0.05. 
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Figure 27: Model of secondary transplant with LT-HSCs as primary donor 
cells. 
After 24 weeks of primary transplant, 1X106 MNCs isolated from the recipients of 
either WT or S6K1-/- LT-HSCs and transplanted into lethally irradiated F1 
recipients. Peripheral blood was obtained from the secondary recipients at 
different time points and analyzed for engraftment of donor-derived cells by flow 
cytometry.  
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Figure 28: S6K1 deficiency causes reduced self-renewal of HSCs. 
(A) Representative flow plot of peripheral blood of secondary transplant
recipients of either WT or S6K1-/- LT-HSCs after 4 weeks and 24 weeks of 
transplantation. After 24 weeks of primary transplant, 1X106 MNCs isolated from 
the recipients of either WT or S6K1-/- LT-HSCs and transplanted into lethally 
irradiated F1 recipients. Peripheral blood was obtained from the secondary 
recipients at different time points and analyzed for engraftment of donor-derived 
cells by flow cytometry. (B) Quantitative representation of donor-derived cells in 
peripheral blood of secondary transplant recipients with cells derived from 
primary transplant recipients of either WT or S6K1-/- LT-HSCs; n=9-10 mice in 
each group. Data are expressed as mean ± SEM. Difference between the 
group means was analyzed by one-way ANOVA with Bonferroni post-hoc 
analysis; *p<0.05.
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Figure 29: S6K1 deficiency causes reduced engraftment of HSCs into BM of 
secondary transplant recipients. 
(A) Representative dot plot of CD45.2+ cells in bone marrow of secondary
recipients after 24 weeks. (B) Quantitative representation of donor-derived cells 
in BM of primary and secondary transplant recipients of either WT or S6K1-/- LT-
HSCs after 24 weeks of transplantation; n=6-10 mice in each group. Data are 
expressed as mean ± SEM. Difference between the group means was analyzed 
by one-way ANOVA with Bonferroni post-hoc analysis; *p<0.05. 
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persists upon another round of serial transplant, we performed tertiary transplant 
with BM MNCs derived from secondary transplant recipients. The donor-derived 
cells in the peripheral blood of the tertiary recipients bearing S6K1-/- HSCs was 
also significantly reduced compared to WT controls (Figure 30A and B). P21 has 
been identified as a key regulator of HSC self-renewal and deficiency of p21 
impairs the self-renewal ability of HSCs (Cheng et al., 2000). We sorted donor-
derived LSK cells (CD45.2+ LSK) cells from bone marrow of WT and S6K1-/- 
secondary recipients and analyzed the expression level of genes regulating the 
self-renewal of HSCs. The expression of p21 was significantly reduced in LSK 
cells isolated from S6K1-/- recipients of secondary transplant (Figure 31). We 
did not observe any change in Pten, Bmi1, PU1, Foxo3 and Meis1 expression in 
LSK cells isolated from S6K1-/- recipients (Figure 31). 
Overexpression of S6K1 in HSC/Ps:  
Multiple studies had demonstrated that both hyperactivation of mTORC1 
(Chen et al., 2008; Kharas et al., 2010; Yilmaz et al., 2006b) and inhibition of 
mTORC1 (Guo et al., 2013; Haneline et al., 2006; Juntilla et al., 2010) activity 
results in defect in HSC functions. Given the importance of maintenance of 
critical level of activation of upstream effectors of S6K1 in regulation of functions 
of HSC functions, we hypothesized that S6K1 expression and activity level might 
be a critical regulator of engraftment and self-renewal of HSCs. We 
overexpressed murine S6K1 in WT HSC/Ps and determined the expression and 
activation level of S6K1. WT HSC/Ps were transduced with either MIEG3 or 
S6K1 and sorted to homogeneity by FACS according to GFP expression. As 
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Figure 30: S6K1 deficiency causes reduced self-renewal of HSCs in tertiary 
recipients. 
Quantitative representation of donor-derived cells in peripheral blood of tertiary 
transplant recipients with cells derived from secondary transplant recipients of 
either WT or S6K1-/- LT-HSCs. After 24 weeks of secondary transplant, 1X106 
MNCs isolated from the recipients of either WT or S6K1-/- LT-HSCs and 
transplanted into lethally irradiated F1 recipients. Peripheral blood was obtained 
from the tertiary recipients at different time points and analyzed for engraftment 
of donor-derived cells by flow cytometry. n=8-10 mice in each group. Data are 
expressed as mean ± SEM. Difference between the group means was analyzed 
by one-way ANOVA with Bonferroni post-hoc analysis; *p<0.05. 
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Figure 31: S6K1 deficiency causes reduction in p21 expression in LSK cells 
in secondary recipients. 
Quantitative representation of expression level of genes in of donor-derived BM 
LSK (CD45.2+ LSK) cells isolated from secondary transplant recipients. 
Experiment was performed in quadruplicates. Data are expressed as 
mean ± SD; *p<0.05. 
134
compared to empty vector expressing HSC/Ps (MIEG3), cells transduced with 
MIEG3-S6K1 (Figure 32A, Lane2) expressed significantly higher level of S6K1 as 
well as increased activation level compared to cells transduced with empty vector 
(Figure 32A, Lane1).  
We next determined if overexpression of S6K1 renders any proliferative 
advantage to HSC/Ps. We transduced WT HSC/Ps with either MIEG3 or MIEG3-
S6K1 and sorted to homogeneity by FACS according to GFP expression. The 
cells were starved in serum-free media and thymidine incorporation assay was 
performed as described in the materials and methods section. Overexpression of 
S6K1 does not have any effect on proliferation of WT HSC/Ps in presence of 
growth factors (Figure 32B). To determine if the overexpressed protein functions 
similarly like endogenous protein in vitro, we transduced S6K1-/- HSC/Ps with 
either MIEG3 or MIEG3-S6K1 and sorted to homogeneity by FACS according to 
GFP expression. S6K1-/- HSC/Ps transduced with empty vector have 
significantly increased proliferation in presence of growth factors. However, the 
increase in proliferation of S6K1-/- HSCP/s was abrogated when S6K1 is 
overexpressed in S6K1 deficient cells (Figure 32B). Overall, these data suggest 
that overexpression of S6K1 in HSC/Ps result in hyperphosphorylation of S6K1. 
However, the increase in S6K1 activity does not result in increased proliferation 
of HSC/Ps in presence of growth factors. 
Overexpression of S6K1 in HSCs results in reduced self-renewal: 
To determine the functional significance of overexpression of S6K1 in 
HSCs, we performed competitive repopulation assay (Figure 33). Lethally 
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Figure 32: Overexpression of S6K1 in HSC/Ps. 
(A) Expression level of phospho-S6K1 and S6K1 in WT HSC/Ps transduced with 
either MIEG3 or MIEG3-S6K1. ß-Actin was used as a loading control. (B) 
Thymidine incorporation assay with WT and S6K1-/- HSC/Ps transduced with 
MIEG3 or MIEG3-S6K1. WT and S6K1-/- HSC/Ps were transduced with either 
MIEG3 or MIEG3-S6K1 and sorted to homogeneity based on GFP expression. 
Cells were serum starved and plated in absence of growth factors (No GF) or in 
presence of growth factors (SCF, TPO, IL-6, Flt3). After 42 hours, cells were 
pulsed with thymidine and thymidine incorporation into cells were determined 
after 6 hours of pulse. Experiment was performed in quadruplicates. Data are 
expressed as mean ± SEM; *p<0.05. 
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Figure 33: Model of primary transplant using HSCs overexpressing S6K1. 
1.5X105 MIEG3 or MIEG3-S6K1 HSCs (GFP+) were mixed with 3X105 MNCs 
isolated from Boy/J mice and transplanted into lethally irradiated Boy/J recipients. 
Peripheral blood was obtained from the recipients at different time points and 
analyzed for engraftment of donor-derived cells (GFP+) by flow cytometry. 
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irradiated mice were transplanted with either WT expressing MIEG3 or MIEG3-
S6K1. Mice transplanted with S6K1 overexpressing HSCs showed significantly 
decreased short-term and long-term engraftment in the peripheral blood of 
recipients compared to MIEG3 recipients that persisted up to 24 weeks after 
transplantation (Figure 34A and B).  
 To determine the effect of S6K1 overexpression and hyperactivation on 
self-renewal on HSCs, BM MNCs were isolated from primary recipients after 24 
weeks post-transplant. GFP+ cells were sorted from BM MNCs derived from 
recipients of either MIEG3 or MIEG3-S6K1 expressing HSCs (Figure 35). Sorted 
cells were mixed with syngenic competitor cells and transplanted into lethally 
irradiated recipients for secondary transplant. Secondary recipients of S6K1 
overexpressing cells had significantly reduced engraftment of GFP+ cells in the 
peripheral blood of recipients compared to controls. The difference in 
engraftment of S6K1 overexpressing cells persisted from week 4 to week 18 
post-transplant (Figure 36A and B). We next analyzed the engraftment of GFP+ 
cells in the BM of the secondary recipients after 18 weeks post-transplant. The 
recipients of S6K1 overexpressing HSCs also showed significantly reduced 
GFP+ BM MNCs compared to controls (Figure 37A and B). 
 Previous studies have demonstrated that deficiency in Akt activity results 
in reduced engraftment and self-renewal of HSCs (Juntilla et al., 2010). As 
described previously, S6K1 is a regulator of Akt activation through a negative 
feedback loop in which S6K1 directly regulates mTORC2 activity (Julien et al., 
2010). We determined the effect of S6K1 overexpression on Akt activity. We 
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Figure 34: Hyperactivation of S6K1 causes reduced engraftment of HSCs in 
primary transplant recipients. 
(A) Representative flow plot of peripheral blood of primary transplant recipients of
either WT HSCs transduced with either MIEG3 or MIEG3-S6K1 at 4 and 24 
weeks after transplantation. Peripheral blood was obtained from the recipients at 
different time points and analyzed for engraftment of donor-derived cells (GFP+) 
by flow cytometry. (B) Quantitative representation of donor-derived cells in 
peripheral blood of primary transplant recipients of WT HSCs transduced with 
either MIEG3 or MIEG3-S6K1; n=4-6 mice in each group. Data are expressed 
as mean ± SEM; *p<0.05. 
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Figure 35: Model of secondary transplantation with HSCs overexpressing 
S6K1. 
At 24 weeks after primary transplant, 5X105 MIEG3 or MIEG3-S6K1 BM MNCs 
(GFP+) were sorted from primary transplant recipients, mixed with 5X105 MNCs 
isolated from Boy/J mice and transplanted into lethally irradiated Boy/J recipients. 
Peripheral blood was obtained from the recipients at different time points and 
analyzed for engraftment of donor-derived cells by flow cytometry 
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Figure 36: Hyperactivation of S6K1 causes reduced self-renewal of HSCs. 
(A) Representative flow plot of peripheral blood of secondary transplant
recipients of either WT HSCs transduced with either MIEG3 or MIEG3-S6K1 after 
4 and 18 weeks of transplantation. At 24 weeks after primary transplant, 5X105 
MIEG3 or MIEG3-S6K1 HSCs (GFP+) were sorted from primary transplant 
recipients, mixed with 5X105 MNCs isolated from Boy/J mice and transplanted 
into lethally irradiated Boy/J recipients. Peripheral blood was obtained from the 
recipients at different time points and analyzed for engraftment of donor-derived 
cells by flow cytometry. (B) Quantitative representation of donor-derived cells in 
peripheral blood of secondary transplant recipients of WT HSCs transduced with 
either MIEG3 or MIEG3-S6K1; n=7 mice in each group. Data are expressed as 
mean ± SEM; *p<0.05. 
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Figure 37: Hyperactivation of S6K1 causes reduced engraftment of HSCs in 
BM of secondary recipients. 
(A) Representative flow plot of donor-derived cells (GFP+) in BM of secondary
transplant recipients at 18 weeks after secondary transplant. (B) Quantitative 
representation of donor-derived cells in BM of secondary transplant recipients of 
WT HSCs transduced with either MIEG3 or MIEG3-S6K1; n=7 mice in each 
group. Data are expressed as mean ± SEM; *p<0.05. 
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transduced WT HSC/Ps with either empty vector or S6K1 and sorted the cells to 
homogeneity based on GFP expression and protein expression level was 
determined as described in the materials and methods section. Akt 
phosphorylation on Ser-473 was significantly reduced in HSC/Ps 
overexpressing S6K1 (Figure 38, Lane 2) as compared to controls (Figure 38, 
Lane 1). Overall, these data suggest that hyperactivation of S6K1 in HSCs 
results in reduced engraftment and self-renewal, which is associated with 
reduced activation of Akt in HSC/Ps. 
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Figure 38: Hyperactivation of S6K1 results in increased Akt 
phosphorylation in HSC/Ps. 
(A) Expression level of phospho-Akt in WT HSC/Ps transduced with either
MIEG3 or MIEG3-S6K1. WT HSC/Ps were transduced with either MIEG3 or 
MIEG3-S6K1 and sorted based on GFP expression. Sorted cells were cultured in 
vitro. Ten million cells in each group were serum starved and protein was 
extracted. Proteins were separated by immunoblotting and probed with antibody 
against phosphorylated form of Akt. ß-Actin was used as a loading control. Data 
representative of two independent experiments. (B) Quantitative representation 
of relative density of phospho-Akt normalized to ß-Actin expression level. 
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Discussion: 
The role of activators as well as inhibitors of S6K1 activity in regulation of 
HSC function have been studied in detail (Juntilla et al., 2010; Lee et al., 2010; 
Magee et al., 2012). However, the exact role of S6K1 expression and activity 
level in regulation of HSC function has not been studied before. Our data 
establishes that the level of S6K1 activation is critical for the self-renewal of 
HSCs. In the primary transplant, the engraftment potential of HSCs can be 
evaluated in a competitive setting, while in secondary transplant the self-renewal 
potential of HSCs can be determined. We found no significant differences in the 
homing and long-term engraftment of S6K1-/- HSCs in primary recipients. These 
data suggest that S6K1 does not regulate homing and long-term engraftment of 
HSCs in primary recipients. Our studies also show that S6K1 does not regulate 
short-term engraftment of HSCs when highly purified HSCs were used as test 
cells in a competitive assay. However, there were significant differences in 
engraftment of donor-derived cells in secondary transplant recipients as well as 
tertiary transplant recipients. This indicates that S6K1 is a positive regulator of 
self-renewal of HSCs. This defect in self-renewal could arise from reduced cell 
cycling or homing of S6K1-defcient HSCs derived from primary recipients. 
Further studies on homing and cell-cycle status of cells derived from primary 
recipients are required to identify the exact physiological mechanisms 
responsible for reduced self-renewal of S6K1-/- HSCs. 
Previous studies have shown that deletion of mTOR results in reduced 
engraftment of HSCs in primary transplant recipients (Guo et al., 2013). Similarly, 
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Akt1 and Akt2 deficient HSCs have decreased engraftment in primary transplant 
recipients (Juntilla et al., 2010). As activation of mTORC1 results in inactivation 
of 4E-BP1 and activation of S6K1, it could be possible that both events are 
required for engraftment of HSCs in primary recipients. However, loss of 
expression of S6K1 does not affect long-term engraftment in primary recipients, 
but results in reduced self-renewal of HSCs following serial transplantation. By 
using genetic models, it has been established that loss of mTORC1 activity 
results in reduced engraftment and self-renewal of HSCs in mice (Guo et al., 
2013; Haneline et al., 2006; Juntilla et al., 2010). However, inhibition of mTORC1 
activity in HSCs by using pharmacological inhibitors in human and murine HSCs 
has yielded contradictory results. In ex-vivo culture of murine HSC enriched 
population, treatment with rapamycin results in expansion of phenotypically 
defined HSC enriched population (Luo et al., 2014). Furthermore, rapamycin 
treatment increases long-term engraftment of murine HSCs (Luo et al., 2014). 
Treatment of human UCB CD34+ cells with rapamycin results in increased 
engraftment and self-renewal following serial transplantation (Rohrabaugh et al., 
2011). This difference in functional outcome could also be due to differential 
regulation of p21 in different models. In our study, we show that expression level 
of p21 was significantly down-regulated in S6K1-/- LSK cells isolated from BM of 
secondary recipients. Cheng et al. have demonstrated that p21 deficient HSCs 
displays reduced self-renewal potential and exhaust upon serial transplant and 
from quaternary transplant have significantly reduced repopulating ability, which 
indicates a decline in self-renewal (Cheng et al., 2000). On the other hand, 
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previous studies have shown that rapamycin increases p21 expression. 
Rapamycin treatment results in increased p21 expression level in response to 
TGF-ß (Law et al., 2002). TGF-ß1 is a positive regulator of quiescence and 
previous studies have demonstrated its inhibitory effect on HSC and HPC 
proliferation (Ohta et al., 1987; Ottmann and Pelus, 1988; Yamazaki et al., 2009). 
TGF-ß1 treatment of human UCB CD34+ cells upregulates p21 mRNA 
expression level (Ducos et al., 2000). It is possible that rapamycin treatment 
increases p21 expression level in HSCs that results in increased self-renewal 
potential of HSCs. Lee et al. have demonstrated that peroxisome proliferator-
activated receptor (PPAR)-γ and retinoic acid X receptor (RXR)-α heterodimer 
represses TGF-ß1 expression level by inhibiting S6K1 activation (Lee et al., 
2006). Loss of S6K1 expression in HSCs could result in decreased TGF-ß1 
expression, which in turn downregulates p21 expression in S6K1-/- HSCs. The 
increase in long-term engraftment following rapamycin treatment could be also 
due to increased expression level of Bmi1 in HSCs following rapamycin 
treatment (Luo et al., 2014). Bmi1 represses p16 expression level thus 
decreasing cellular senescence in HSCs (Park et al., 2003) and inhibition of p16 
activity has been associated with increase in HSC function (Janzen et al., 2006). 
Interestingly, our studies also provide evidence that expression and 
activation level of S6K1 is critical for engraftment and self-renewal of HSCs. In 
this study, we have shown that loss of expression of S6K1 in HSCs as well as 
overexpression and hyperactivation of S6K1 in HSCs results in reduced 
engraftment and self-renewal of HSCs. We also show that Akt activity is 
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diminished following overexpression of S6K1 in HSC/Ps. As loss of Akt activity 
results in decreased engraftment of HSCs, the reduction in engraftment of HSCs 
following overexpression of S6K1 could be due to reduced Akt activity (Juntilla et 
al., 2010). S6K1 has been identified as a negative regulator of mTORC2-
dependent activation of Akt. SIN1 and Rictor are two components of mTORC2 
complex and both are required for mTORC2-dependent phosphorylation of Akt 
(Yang et al., 2006). In MEF, S6K1 phosphorylates SIN1 at Thr-86 and Thr-398 
thus impairing mTORC2 activity (Figure 39A) (Liu et al., 2013). In MEFs, 
following mTORC1-dependent activation, S6K1 also phosphorylates Rictor, 
another component of mTORC2, at Thr-1135 (Figure 39A) (Julien et al., 2010). 
Phosphorylation of Rictor at Thr-1135 by S6K1 results in inhibition of Akt activity 
(Julien et al., 2010). It is probable that following overexpression of S6K1 in 
HSC/Ps, the reduction in Akt activation could be due to inhibition of mTORC2 
activity by hyperactivated S6K1 (Figure 39B). 
It has been shown previously that either hyperactivation or loss of function 
of PI3K-mTORC1 pathway negatively regulates the functions of HSCs (Campbell 
et al., 2009; Chen et al., 2008; Guo et al., 2013; Haneline et al., 2006; Juntilla et 
al., 2010; Kharas et al., 2010; Lee et al., 2010; Yilmaz et al., 2006b). However, 
these studies involved a single approach involving either loss of expression or 
overexpression of a single component of the PI3K-mTORC1 pathway. In our 
studies, we provide compelling evidence that both loss of expression and gain of 
expression of a single component of PI3K-mTORC1 pathway have the same 
impact on the functional potential of HSCs. The dependency of HSCs on a 
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Figure 39: Proposed mechanism of effect of S6K1 overexpression on Akt-
mTORC activity in HSCs. 
A schematic model of potential signaling pathways that could affect Akt activity 
based on the evidence provided in our studies as well as current literature. (A) In 
normal HSCs, mTORC2 acts an activator of Akt. S6K1 exerts an inhibitory effect 
on mTORC2 thus negatively regulating Akt phosphorylation. (B) Following 
overexpression of S6K1, S6K1-mediated inhibition of mTORC2 is increased 
which results in downregulation of Akt activity in HSCs. 
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threshold level of a single factor have been described before. HSCs deficient in 
both Akt1 and Akt2 displayed significantly reduced differentiation compared to 
controls along with reduced ROS level (Juntilla et al., 2010). However, the 
differentiation of Akt1 and Akt2 deficient HSCs significantly increased following 
increase in ROS level (Juntilla et al., 2010). On the other hand, in Foxo or Atm 
deficient mice, HSCs display an increase in ROS level, which causes exhaustion 
of HSC pool (Ito et al., 2004; Tothova et al., 2007). Treatment with N-acetyl-
Lcysteine, an antioxidative agent, which decreases cellular ROS level, reverses 
the phenotype of Atm or Foxo deficient HSCs (Ito et al., 2004; Tothova et al., 
2007). Zhou et al. have demonstrated that rotenone inhibits S6K1 activity and 
increases the ROS level in neurons. In astrocytes, ischemia induced by oxygen 
and glucose deprivation causes increased ROS level, which was associated with 
decreased S6K1 activity (Zhou et al., 2015). It is probable that S6K1 activity 
regulates the critical ROS level that is required for proper functioning of HSCs. 
Additionally, the importance of critical S6K1 level has been described before. A 
study by Yang et al. has shown that in PTEN deficient neurons, both 
overexpression or loss of expression of S6K1 results in reduced axon 
regeneration (Yang et al., 2014). It is probable that in HSCs too, a critical level of 
S6K1 is required to maintain self-renewal. 
In summary, we have defined the role of S6K1 in self-renewal, 
engraftment and differentiation of HSCs. Following serial transplantation, S6K1-/- 
HSCs had significantly decreased engraftment in the recipients. However, 
hyperactivation of S6K1 in HSCs also results in reduced engraftment in 
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recipients upon serial transplantation. Taken together, these data suggest that 
activation level of S6K1 is critical for maintenance of self-renewal potential of 
HSCs. Previous studies have shown that hyperactivation of mTORC1 or loss of 
function of mTORC1 causes reduced engraftment of HSCs. Our data indicate 
S6K1 could be the key regulator of mTORC1 functions in regulation of self-
renewal of HSCs. Our study also establishes that S6K1 deficiency does not 
affect differentiation or homing of HSCs in primary transplant recipients. We have 
showed that p21 expression is reduced in S6K1-/- HSCs derived from secondary 
recipients. We also provide evidence that hyperactivation of S6K1 results in 
reduced activation of Akt in HSC/Ps. We hypothesize that this reduction in Akt 
activation could be due to reduced mTORC2 activity in HSCs overexpressing 
S6K1 (Figure 39B).  
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Chapter 6: S6K1 is a positive regulator of propagation of 
acute myeloid leukemia 
Introduction: 
Previous studies from our group and others have established that PI3K-
mTORC1 pathway, of which S6K1 is a part of, plays an essential role in 
regulating myeloproliferative neoplasms. Pharmacological inhibition of PI3K, Akt 
or mTORC1 results in reduced S6K1 activity (Boulay et al., 2004; Liu et al., 
2014a; Xin et al., 2014). Furthermore, PI3K, Akt and mTORC1, the upstream 
regulators of S6K1 activation, have been identified as critical mediators of 
myeloproliferative neoplasms. Previous studies from our lab have shown that p85 
regulatory subunit of PI3K regulates c-Kit D814V mutation induced 
transformation in murine cells. We have also demonstrated that inhibition of p85α 
activity in oncogenic c-Kit expressing cells is sufficient to suppress growth and 
leukemogenesis (Munugalavadla et al., 2007; Munugalavadla et al., 2008). 
Consistently, pharmacologic inhibition of mTORC1 activity is sufficient to inhibit 
the growth of oncogenic c-Kit expressing cells (Munugalavadla et al., 2007). The 
p110δ catalytic subunit of PI3K, is the primarily upregulated PI3-K isoform in 
AML cells (Sujobert et al., 2005). Combined inhibition of p110δ activity and 
mTORC1 activity results in increased apoptosis and reduced survival of AML 
cells compared to individual inhibition of either mTORC1 or p110α (Colamonici et 
al., 2015).  
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Deletion of PTEN, a negative regulator of S6K1 activation, results in 
leukemogenesis in mice (Yilmaz, 2006). Pharmacological inactivation of 
mTORC1 activity in PTEN-deficient mice prolongs their survival, which suggests 
that PTEN-deficient AML cells require S6K1 for leukemogenesis (Yilmaz et al., 
2006b). Dysregulated PTEN transcript level in AML patients have been 
associated with increased activation of Akt and poor prognosis in AML patients 
(Cheong et al., 2003). Older AML patients who are negative for or lack PTEN 
expression but are positive for the expression of CD44 demonstrate poor overall 
survival (Huang et al., 2015). As S6K1 and mTORC1 remains hyperactive in 
PTEN deficient hematopoietic cells (Magee et al., 2012), it is important to 
understand the role of S6K1 in AML to determine if S6K1 is critical for 
leukemogenesis. 
 Akt is phosphorylated at Thr-308 and Ser-473 in 50-72% of AML patients 
(Tamburini, 2007; Min, 2003). Phosphorylation on either of the residues of Akt is 
associated with poor overall survival in AML patients. The PI3-K pathway in AML 
cells can also be hyperactivated because of activation of the IGF-1/IGF-1R 
autocrine loop (Chapuis et al., 2010a). Deletion of Raptor, a component of 
mTORC1, results in delayed AML progression in vivo (Hoshii et al., 2012). 
Deficiency of Raptor induces apoptosis selectively in differentiated AML cells, but 
not in undifferentiated AML cells, which might result in delayed AML progression 
in mice (Hoshii et al., 2012). Furthermore, S6K1 phosphorylation level is 
decreased in Raptor-deficient AML cells (Hoshii et al., 2012). There is evidence 
suggesting that oncogenes could regulate mTORC1 activation bypassing Akt. 
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Cells bearing FMS-like tyrosine kinase-3 internal tandem duplication (FLT3-ITD) 
activates Stat5, which results in mTORC1 activation, rendering the cells resistant 
to PI3K-Akt inhibitor (Nogami et al., 2015). This study suggests mTORC1 can be 
activated in AML cells by oncogenic receptors through a mechanism that is 
independent of Akt activation. This evidence emphasizes the fact that the 
detailed study of S6K1, a downstream effector of mTORC1, is required to 
understand the role of mTORC1 activation in AML.  
In this chapter, we show that S6K1 delays the propagation of AML 
inn secondary recipients, but does not play a role in leukemia initiation and 
progression. Furthermore, mTORC1 activity is reduced in S6K1 deficient AML 
cells. We also demonstrate that PF-4708671, a specific inhibitor of S6K1, can 
inhibit the growth of human leukemic cells in vitro and inhibits mTORC1 activity. 
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Results:  
Deficiency of S6K1 in HSC/Ps does not affect leukemia initiation and 
progression:  
Based on previous studies demonstrating the importance of mTORC1 
activation in AML, we hypothesized that S6K1 is a regulator of leukemia initiation, 
progression and propagation by serial transplantation. We used a well-defined 
model of AML due to translocation in the MLL gene (Goyama et al., 2013; Harris 
et al., 2012; Neff et al., 2012). Previous studies have demonstrated that 
transplantation of WT HSC/Ps expressing MLL-AF9 result in myeloid expansion 
of HSC/Ps and recipient mice develops AML characterized by increased WBC 
count in peripheral blood along with splenomegaly (Goyama et al., 2013; Harris 
et al., 2012; Neff et al., 2012). To test our hypothesis, WT and S6K1-/- HSC/Ps 
were transduced with MLL-AF9 and transplanted into lethally irradiated mice. We 
monitored the transplant recipients for WBC counts in the peripheral blood and 
engraftment of donor cells. At 28 days post-transplant, both groups of mice had 
increased WBC count in the peripheral blood (Figure 40A). Furthermore, there 
were no differences in the engraftment of donor cells in the peripheral blood of 
the recipients of WT and S6K1-/- HSC/Ps bearing MLL-AF9 (Figure 40B, left 
panel; Figure 40C). We analyzed peripheral blood of the recipients of WT and 
S6K1-/- HSC/Ps bearing MLL-AF9 for differentiation of cells into myeloid cells. In 
peripheral blood of WT and S6K1-/- HSC/Ps bearing MLL-AF9, GFP+ cells were 
of myeloid lineage as determined by the expression of Gr1 and Mac1 on the cell 
surface (Figure 40B, right panel; Figure 40D). The primary transplant recipients 
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Figure 40: Increased WBC counts and expansion of myeloid cells in 
primary transplant recipients of HSC/Ps expressing MLL-AF9. 
(A) Quantitative representation of WBC count in primary transplant recipients of
WT and S6K1-/- HSC/Ps expressing MLL-AF9. (B) Representative flow plot of 
GFP+ cells and GFP+ myeloid cells in peripheral blood of primary recipients of 
WT and S6K1-/- HSC/Ps expressing MLL-AF9. (C) Quantitative representation of 
GFP+ cells in peripheral blood of primary recipients. (D) Quantitative 
representation of GFP+ myeloid cells (Gr1+, Mac1+, Gr1+Mac1+) in peripheral 
blood of primary recipients. Data are expressed as mean ± SEM; n=11-12 mice 
in each group. 
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in both groups developed myeloid leukemia around day 40 (Figure 41A) and 
developed splenomegaly (Figure 41B). There was no difference in the median 
survival of both groups bearing MLL-AF9 (Figure 41A). We analyzed the bone 
marrow of mice with AML to determine the engraftment of donor-derived cells. 
There was no difference in the engraftment of GFP+ cells within the bone marrow 
of WT and S6K1-/- groups that developed AML (Figure 41C, top panel). When 
we further analyzed the differentiation of GFP+ cells, most of the cells in the 
GFP+ fraction were myeloid cells (Gr1+, Mac1+) in both groups of recipients 
(Figure 41C, bottom panel).  
Deficiency of S6K1 delays propagation of leukemia by AML cells: 
Previous studies have demonstrated that cells bearing MLL-AF9 fusion 
gene isolated from primary recipients who have developed AML, can propagate 
AML in secondary recipients (Harris et al., 2012; Neff et al., 2012). To determine 
the role of S6K1 in leukemia propagation, we transplanted lethally irradiated mice 
with splenocytes derived from primary transplant recipients who developed AML 
(Goyama et al., 2013). The engraftment of GFP+ Mac1+ cells in splenocytes of 
primary recipients were similar in two groups (Figure 42A and B). Following 
transplantation, the survival of secondary transplant recipients of cells derived 
from S6K1-/- primary transplant recipients was prolonged significantly compared 
to controls (Figure 42C). The median survival time of S6K1-/- recipients was 24 
days compared to median survival of 7 days in WT controls (Figure 42C). We 
analyzed the peripheral blood and bone marrow of secondary transplant 
recipients to determine the engraftment of donor cells. The engraftment of GFP+ 
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Figure 41: S6K1 does not affect leukemia initiation and progression in 
primary recipients. 
(A) Kaplan-Meier survival curve of primary recipients of WT and S6K1-/- HSC/Ps
expressing MLL-AF9. Statistical significance between the survival of two groups 
was analyzed by the log-rank (Mantel-Cox) test. n=15-19 mice in each group. 
(B) Spleens isolated from WT and S6K1-/- primary recipients. (C)
Representative flow plot and quantitative representation of GFP+ cells in BM of 
primary recipients of WT and S6K1-/- HSC/Ps expressing MLL-AF9 (top panel). 
Representative flow plot and quantitative representation of GFP+ myeloid cells 
(Gr1+, Mac1+, Gr1+Mac1+) in BM of primary recipients of WT and S6K1-/- 
HSC/Ps expressing MLL-AF9 (bottom panel). Data are expressed as mean ± 
SEM; n=5 mice in each group. 
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Figure 42: S6K1 deficiency delays propagation of leukemia. 
(A) Representative flow plot of GFP+ Mac1+ cells in spleen of primary recipients
of WT and S6K1-/- HSC/Ps expressing MLL-AF9. (B) Quantitative representation 
of GFP+ Mac1+ cells in spleen of primary recipients of WT and S6K1-/- HSC/Ps 
expressing MLL-AF9. n=5 mice in each group.  (C) Kaplan-Meier survival curve 
of secondary transplant recipients of WT and S6K1-/- HSC/Ps expressing MLL-
AF9. Statistical significance between the survival of two groups was analyzed by 
the log-rank (Mantel-Cox) test; n=17 mice in each group; *p<0.01. 
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cells in peripheral blood of secondary recipients was similar in two groups (Figure 
43A, top panel and B, left panel). Additionally, the GFP+ cells in both groups 
demonstrated expression of Gr1 and Mac1, which indicates expansion of myeloid 
cells (Figure 43A, bottom panel and B, right panel). Furthermore, the engraftment 
of GFP+ cells in bone marrow of secondary recipients was similar in two groups 
(Figure 44A, top panel and B). Additionally, the GFP+ cells in both groups 
demonstrated expression of Gr1 and Mac1 to a similar level, which indicates 
expansion of myeloid cells (Figure 44A, bottom panel and C). Overall, these data 
suggest that deficiency of S6K1 does not affect leukemia initiation and 
progression in primary recipients, but delays the propagation of leukemia through 
serial transplantation. 
S6K1 deficiency reduces Akt activation in MLL-AF9 bearing cells: 
S6K1 has been identified as a negative regulator of Akt activation (Treins 
et al., 2010; Um et al., 2004) and previous studies have demonstrated that Akt is 
hyperactivated in MLL-AF9 bearing cells (Chapuis et al., 2010b; Hoshii et al., 
2012). MOLM-13 cells, a human cell line expressing MLL-AF9, show constitutive 
activation of Akt, which is inhibited upon treatment with rapamycin or BEZ-235, a 
dual PI3K/mTORC1/C2 inhibitor (Chapuis et al., 2010b). To assess if S6K1 
induced transformation in the context of MLL is in part mediated via hyperactive 
Akt, we analyzed phosphorylation level of Akt in the presence or absence of 
SK61. We expressed MLL-AF9 in WT and S6K1-/- HSC/Ps and sorted the cells 
to homogeneity based on GFP expression. Cells were analyzed for expression 
and activation of Akt. In WT HSC/Ps expressing MLL-AF9 (Figure 45A, Lane 1), 
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Figure 43: Engraftment of donor cells in peripheral blood of secondary 
transplant recipients. 
(A) Representative flow plot of GFP+ cells in peripheral blood of secondary
recipients of WT and S6K1-/- HSC/Ps expressing MLL-AF9 (top panel). 
Representative flow plot of GFP+ myeloid cells (Gr1+, Mac1+, Gr1+Mac1+) in 
peripheral blood of secondary recipients of WT and S6K1-/- HSC/Ps expressing 
MLL-AF9 (bottom panel). (B) Quantitative representation of GFP+ cells in
peripheral blood of secondary recipients of WT and S6K1-/- HSC/Ps expressing 
MLL-AF9 (left panel). Quantitative representation of GFP+ myeloid cells (Gr1+,
Mac1+, Gr1+Mac1+) in peripheral blood of secondary recipients of WT and 
S6K1-/- HSC/Ps expressing MLL-AF9 (right panel). Data are expressed as 
mean ± SEM; n=5 mice in each group. 
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Figure 44: Engraftment of donor cells in bone marrow of secondary 
transplant recipients. 
(A) Representative flow plot of GFP+ cells in BM of secondary recipients of WT
and S6K1-/- HSC/Ps expressing MLL-AF9 (top panel). Representative flow plot 
of GFP+ myeloid cells (Gr1+, Mac1+, Gr1+Mac1+) in BM of secondary recipients 
of WT and S6K1-/- HSC/Ps expressing MLL-AF9 (bottom panel). (B) Quantitative 
representation of GFP+ cells in BM of secondary recipients of WT and S6K1-/- 
HSC/Ps expressing MLL-AF9. (C) Quantitative representation of GFP+ myeloid 
cells (Gr1+, Mac1+, Gr1+Mac1+) in BM of secondary recipients of WT and 
S6K1- /- HSC/Ps expressing MLL-AF9. Data are expressed as mean ± SEM; n=5 
mice in each group. 
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Figure 45: S6K1 deficiency causes reduction in Akt and mTORC1 activation 
in MLL-AF9 expressing cells.  
(A) WT and S6K1-/- HSC/Ps were transduced with MLL-AF9 fusion oncogene.
Cells were sorted based on GFP expression and expanded in vitro. Cells were 
serum-starved for 6 hours and protein was extracted. Phosphorylation level of 
Akt and 4E-BP1 was detected by immunoblotting. Akt and β-Actin was used as 
loading control. Data representative of three independent experiments. (B) 
Quantitative analysis of relative density of phospho-Akt and phospho-4E-BP1.  
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we observed phosphorylation of AKt, which was significantly reduced in MLL-AF9 
cells in the absence of S6K1 (Figure 45A, Lane 2; Figure 45B). As Akt is an 
upstream positive regulator of mTORC1 activity, we next analyzed the 
phosphorylation of 4E-BP1, which is a downstream substrate of mTORC1. 4E-
BP1 is phosphorylated and inactivated following activation of mTORC1. Previous 
studies have shown that 4E-BP1 remains hyperphosphorylated in AML cells, 
which indicates increased Akt-mTORC1 activity. S6K1-/- HSC/Ps bearing MLL-
AF9 (Figure 45A, Lane 2; Figure 45B) showed reduced 4E-BP1 phosphorylation 
compared to WT HSC/Ps expressing MLL-AF9 (Figure 45A, Lane 1; Figure 45B). 
These data suggest that following loss of S6K1 expression in HSC/Ps bearing 
MLL-AF9, the mTORC1 activity is decreased which might delay leukemia
propagation seen in our studies. 
Inhibition of S6K1 activity results in decreased proliferation of human 
leukemic cells bearing the MLL-AF9 translocation: 
Activation of mTORC1 and mTORC2 plays a critical role in regulation of 
growth of human leukemic cells (Tamburini et al., 2009). Pharmacological 
inhibition of mTORC activity in cells derived from AML patients results in cell 
death. Moreover, S6K1 has been shown to be constitutively active in cells 
obtained from AML patients (Sujobert et al., 2015). We therefore evaluated if 
inhibition of S6K1 in human cell lines bearing MLL-AF9 can inhibit the 
proliferation of leukemic cells. We have used PF-4708671, a cell permeable 
compound that specifically inhibits S6K1 activity, (Pearce et al., 2010) and UCB 
CD34+ cells expressing MLL-AF9 fusion oncoprotein for our studies. PF-
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4708671 is a piperazinyl-pyrimidine analogue that specifically inhibits S6K1 
activity without significantly inhibiting activity of other AGC kinases (Pearce et al., 
2010). Furthermore, in HEK-294 cells, PF-4708671 does not inhibit Akt or 
mTORC1 activity (Pearce et al., 2010). MA9-3 cells are human UCB CD34+ cells 
transformed and immortalized by expressing MLL-AF9 (Wei et al., 2008). These 
cells display a myeloid phenotype and can initiate leukemia in vivo (Wei et al., 
2008). We serum starved the cells and performed thymidine incorporation assay 
with different concentration of PF-4708671 in presence or absence of growth 
factors. We observed a dose-dependent decrease in proliferation of MA9-3 cells 
following treatment with PF-4708671 (Figure 46). To determine the possible 
mechanism for growth repression of human AML cells following S6K1 inhibition, 
we analyzed activation level of mTOR and 4E-BP1 following S6K1 inhibition. In 
presence of S6K1 inhibitor, the phosphorylation level of mTOR was significantly 
downregulated compared to vehicle treated cells (Figure 47A and C). 
Phosphorylation level of 4E-BP1, a downstream substrate of mTORC1, was also 
downregulated (Figure 47B and C). These data suggest that inhibition of S6K1 
results in reduced mTORC1 activity and attenuates proliferation of human 
leukemic cells. 
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Figure 46: Inhibition of S6K1 activity results in reduced proliferation of 
MLL-AF9 expressing human cells.
Thymidine incorporation assay was performed with MA9-3 cells in absence or 
presence of PF-4708671. Cells were serum starved and plated in absence of 
growth factors (NGF) or in presence of growth factors along with increasing 
concentration of PF-4708671. After 42 hours, cells were pulsed with thymidine 
and thymidine incorporation into cells were determined after 6 hours of pulse. 
Experiment was performed in quadruplicates. Data are expressed as 
mean ± SEM; *p<0.05. 
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Figure 47: Inhibition of S6K1 activity results in reduced mTORC1 activation 
in MLL-AF9 expressing human cells.  
(A) MA9-3 cells were treated with increasing doses of PF-4708671 and phospho-
mTOR level was analyzed by immunoblotting. β-Actin was used as loading 
control. (B) MA9-3 cells were treated with increasing doses of PF-4708671 and 
phospho-4E-BP1 level was analyzed by immunoblotting. S6 was used as loading 
control. Data representative of three independent experiments. (C) Quantitative 
analysis of relative density of phospho-mTOR and phospho-4E-BP1.  
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Discussion: 
While previous studies have established that PI3K-mTORC1 axis 
regulates leukemia initiation and progression (Lee et al., 2010; Magee et al., 
2012), the specific role of S6K1, a downstream substrate of mTORC1, has not 
been studied in detail. The PI3K-mTORC1 pathway is hyperactivated in a large 
section of AML patients (Chapuis et al., 2010a; Chapuis et al., 2010b; Chow et 
al., 2006; Kubota et al., 2004; Xu et al., 2003). However, the prognostic value of 
PI3K-mTORC1 pathway in AML remains contradictory. AML patients with 
increased level of phosphorylated Akt in peripheral blood and bone marrow cells 
have significantly shorter median survival time compared to patients with reduced 
phosphorylated Akt (Kornblau et al., 2006). In patients who are older than 60 
years, lack of response to chemotherapy has been associated with hyperactive 
Akt (Kornblau et al., 2010). In another study, Tamburini et al. showed that AML 
patients with hyperactive Akt have an increased overall survival and increased 
relapse free survival compared to patients with reduced Akt phosphorylation at 
Ser473 (Tamburini et al., 2007). They hypothesized that increased PI3K activity 
in immature leukemic cells results in increased number of cells in S phase, which 
make the cells more susceptible to chemotherapeutic agents (Tamburini et al., 
2007). In a CML model of Bcr-Abl driven leukemia, Naka et al. have 
demonstrated that in LICs, Akt activity is suppressed which results in nuclear 
localization of Foxo3a (Naka et al., 2010). LICs are able to evade stress-induced 
depletion in a Foxo3a dependent manner (Naka et al., 2010). Contrarily, in non-
LIC population in CML, inactivation of Akt results in increased Foxo3a activity, 
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which causes cell cycle arrest and apoptosis (Naka et al., 2010). These findings 
are further corroborated in AML caused by translocation of AF9 within MLL. In 
MLL-AF9 expressing AML cells, constitutive activation of Akt results in growth 
arrest of cells and causes increased maturation of cells towards myeloid lineage 
(Sykes et al., 2011). Furthermore, depletion of Foxo1, Foxo3 and Foxo4, which 
act downstream of Akt, result in diminished LIC activity (Sykes et al., 2011). 
Proliferation of myeloid cells is associated with increased intracellular ROS level 
(Saito et al., 2015). Increased ROS level have been associated with acquisition 
of DNA damage and cellular apoptosis (Huang et al., 2003). AML cells 
expressing MLL-AF9 maintain a reduced ROS level (Naka et al., 2010; Saito et 
al., 2015). Increased ROS level in MLL-AF9 expressing cells results in DNA 
damage, which was associated with downregulation of antioxidant genes by 
Foxo group of proteins (Naka et al., 2010; Santos et al., 2014). However, Akt 
driven Foxo3a activity could also regulate self-renewal potential of LICs 
differentially. Although Foxo3a regulates self-renewal of LICs in CML, it does not 
regulate the self-renewal of LICs in blast crisis model of CML (Naka et al., 2010).  
  Previous studies suggest that Foxo group of proteins are a key 
regulator of propagation of CML and AML and this group of proteins are 
regulated by mTORC1 (Naka et al., 2010; Sykes et al., 2011). Inhibition of 
mTORC1 activity in colon cancer cells results in increased translocation of Foxo1 
from nucleus to cytoplasm (Abdelnour-Berchtold et al., 2010). In this study, we 
provided evidence that S6K1 deficiency results in reduced mTORC1 activity as 
phosphorylation of 4E-BP1, a downstream substrate of mTORC1, was reduced 
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in MLL-AF9 cells deficient in S6K1. It could be possible that MLL-AF9 expressing 
cells have increased cytoplasmic Foxo1 level due to diminished mTORC1 activity 
following inhibition of S6K1.  
AML cells are also highly dependent on glycolysis for cellular metabolism 
(Herst et al., 2011). Herst et al. have demonstrated that AML blast cells with high 
glycolysis rate are resistant to chemotherapeutic agent induced apoptosis (Herst 
et al., 2011). Recent study by Saito et al. has shown that MLL-AF9 expressing 
cells are dependent on glucose metabolism (Saito et al., 2015). Disruption of 
glucose metabolism by metabolic stress diminishes the activity of LICs (Saito et 
al., 2015). S6K1 has been established as a positive regulator of glycolysis in 
leukemic cells. In PTEN-deficient hematopoietic cells, inhibition of S6K1 activity 
results in decreased glycolysis and induced apoptosis (Tandon et al., 2011). 
S6K1 is also a positive regulator of glycolysis in Bcr-Abl expressing cells (Barger 
et al., 2013). However, inhibition of S6K1 activity in Bcr-Abl expressing cells did 
not result in induction of apoptosis in the cells (Barger et al., 2013). It is possible 
that MLL-AF9 expressing cells that are deficient in S6K1 have dysregulated 
glucose metabolism, which delayed the propagation of the disease in vivo.  
   In this chapter, we provide evidence that S6K1 regulates the 
propagation of MLL-AF9 expressing AML through serial transplantation. We also 
demonstrate that genetic disruption of S6K1 expression results in reduced 
mTORC1 and mTORC2 activity as both activation of 4E-BP1 and Akt was 
diminished in S6K1 deficient AML cells. Our studies also demonstrate that 
inhibition of S6K1 activity using a specific inhibitor against S6K1 results in 
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reduced growth of human leukemic cells and inhibits mTORC1 activity. We 
propose that in AML cells, S6K1 phosphorylates and activates mTOR, which is a 
common catalytic subunit of both mTORC1 and mTORC2 (Figure 48A). 
mTORC2 further activates Akt which contributes to subsequent hyperactivation 
of mTORC1 in AML cells (Figure 48A). In S6K1-/- AML cells, S6K1-dependent 
phosphorylation of mTOR is withdrawn (Figure 48B). Subsequently, mTORC2 
driven hyperphosphorylation of Akt is decreased which causes downregulation of 
mTORC1 activity (Figure 48B). 
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Figure 48: Proposed schematic model of S6K1 signaling in AML cells 
expressing MLL-AF9.  
(A) S6K1 phosphorylates and activates mTOR, which is a common catalytic 
subunit of both mTORC1 and mTORC2. mTORC2 further activates Akt, which 
contributes to subsequent hyperactivation of mTORC1 in AML cells. (B) In S6K1-
deficient AML cells expressing MLL-AF9, S6K1-dependent phosphorylation of 
mTOR is withdrawn. Subsequently, mTORC2-driven hyperphosphorylation of 
Akt is decreased, which causes downregulation of mTORC1 activity. 
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Chapter 7: Future Directions 
Determining the mechanism of reduced self-renewal of HSCs following 
modulation of S6K1 expression level: 
In the current study, we have demonstrated that S6K1-/- HSCs have 
reduced self-renewal ability when they undergo serial transplant. We have also 
shown that p21 expression is significantly downregulated in S6K1-/- HSCs. 
Although in our studies, S6K1-/- HSCs demonstrate similar functional abilities as 
p21-/- HSCs, the exact physiological mechanism that causes reduced self-
renewal and engraftment of S6K1-/- HSCs has not been identified. It is probable 
that S6K1 deficiency results in a decrease in functional HSCs. Further analysis is 
required to determine the frequency of HSCs in S6K1-/- mice by performing 
limiting dilution assay with different cell doses with WT and S6K1-/- HSCs. In our 
CRA studies, we have used purified HSCs from test groups (WT and S6K1-/-) 
and performed a head-to-head competitive assay with unfractionated BM MNCs 
derived from competitor (Boy/J). However, a more stringent assay could be 
performed by using sorted HSCs as competitor cells instead of BM MNCs. This 
will allow us to determine the functional potential of S6K1-/- HSCs in a head-to-
head setting with WT HSCs. 
Loss of expression of S6K1 does not affect homing and long-term 
engraftment of HSCs in primary recipients. However, it could be possible there is 
a homing or cell cycle defect in S6K1-/- HSCs derived from primary transplant 
recipients, which contributes to reduced engraftment in secondary recipients. To 
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determine the effect of S6K1 deficiency on homing and cell cycle state of HSCs 
derived from primary recipients, further studies are required. To further 
strengthen our data that S6K1 is a positive regulator of p21 expression in HSCs, 
we propose to determine whether restoration of S6K1 expression in S6K1-/- 
HSCs results in upregulation of p21 expression. WT and S6K1-/- HSCs will be 
transduced with either empty vector or retroviral vector encoding S6K1. Following 
sorting of transduced cells based on GFP expression, we will examine the 
expression of p21. As TGF-ß1 regulates p21 expression level following inhibition 
of mTORC1 activity, it is required to determine TGF-ß1 level in response to S6K1 
deficiency (Law et al., 2002). Furthermore, S6K1 has been shown to be a 
negative regulator of mTORC2 and Akt activity in HEK293 cells (Julien et al., 
2010). However, whether this negative feedback loop exists in HSCs or not, is 
unknown. Studies to determine the activation level of mTORC2 and Akt could be 
critical to determine the signaling pathways that cause dysfunction in S6K1-/- 
HSCs. 
 Our studies also provide evidence that overexpression of S6K1 results in 
reduced engraftment of HSCs in primary recipients. The decrease in engraftment 
of HSCs overexpressing HSCs could be due to reduced homing or cell cycle 
status of these cells. Further studies are required to determine the effect of S6K1 
overexpression on homing and cell cycle progression of HSCs. Previous studies 
have established that S6K1 negatively regulates Akt phosphorylation through 
repressing mTORC2 activity (Julien et al., 2010). In our studies, overexpression 
of S6K1 in HSCs results in reduced phosphorylation of Akt. Further biochemical 
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analysis is required to determine the mTORC2 activity in HSCs overexpressing 
S6K1.  
Determining the effect of inhibition of S6K1 activity on human AML cells: 
S6K1 has been shown to be hyperactivated in in various cancer cells 
including AML (Khotskaya et al., 2014; Sujobert et al., 2015). The studies in this 
thesis have established that S6K1 is a critical regulator of MLL propagation. 
However, the precise cellular processes that are dysregulated in S6K1-deficient 
AML cells are not known. Recent studies have demonstrated the importance of 
glucose metabolism in AML cells. Chen et al. have demonstrated that increased 
glycolysis in AML cells results in resistance to chemotherapeutic agents (Chen et 
al., 2014). Furthermore, inhibition of glycolysis in human AML cells renders them 
susceptible to chemotherapy (Chen et al., 2014). Previous studies have shown 
that S6K1 positively regulates glycolysis in different cell types including leukemic 
cells (Barger et al., 2013; Tandon et al., 2011). However, how specific inhibition 
of S6K1 activity will affect the progression of human AML cells are unknown. Our 
preliminary studies indicate that PF-4708671, a specific inhibitor of S6K1, can 
cause growth arrest in human AML cells. Moreover, our preliminary studies 
indicate that inhibition of S6K1 also results in apoptosis in human AML cells in a 
dose-dependent manner (Figure 49). The effect of S6K1 inhibition on human 
AML cells could be further studied in vivo using established xenograft models for 
AML. NOD/LtSz-scid IL2RG–SGM3 (NSGS) mice have been identified as a 
better host for AML xenografts as they constitutively express three human 
cytokines (hSCF, hIL-3, hGM-CSF) (Wunderlich et al., 2010). After 
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Figure 49: Pharmacological inhibition of S6K1 activity results in increased 
apoptosis of human AML cells expressing MLL-AF9. 
MA9-3 cells were treated with increasing doses of PF-4708671 for 18 hours and 
apoptotic cells were determined by staining with Annexin-V and 7-AAD. 
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transplantation of MA9-3 cells, NSGS mice could be treated with PF-4708671 to 
determine if S6K1 inhibition affects development of human AML cells in vivo. 
This would further define the role of S6K1 in initiation and progression of AML.      
Determining the effect of inhibition of S6K1 activity on human HSCs: 
In this study, we have provided compelling evidence that activity level of 
S6K1 is key for self-renewal of murine HSCs. Both loss of expression and gain of 
expression of S6K1 result in reduced self-renewal of murine HSCs. However, 
previous studies have shown that pharmacological inhibition of mTORC1-S6K1 
activity in ex vivo cultured human HSCs result in increased engraftment and self-
renewal in irradiated hosts (Rohrabaugh et al., 2011). There is a possibility that 
mTORC1-S6K1 differentially regulates the HSC functions in mouse and human. 
Our preliminary studies showed that inhibition of S6K1 activity in human UCB 
CD34+ cells results in enrichment of phenotypically defined HSC-enriched 
population (CD34+CD38-). We performed in vitro culture of human UCB derived 
CD34+ cells in presence or absence of S6K1 inhibitor, PF-4708671. After 5 days 
of culture, the frequency of CD34+CD38- cells were significantly increased in 
cells treated with PF-4708671 (Figure 50A and B). This data suggests that 
inhibition of S6K1 activity in ex vivo cultured human HSCs could expand the 
phenotypically defined HSC-enriched population. The expansion of phenotypic 
HSCs might result in increased engraftment and self-renewal of HSCs. However, 
our study also demonstrated that S6K1 is a positive regulator of HSC 
quiescence. It is also possible that inhibition of S6K1 in human HSCs could result 
in decreased quiescence of HSCs, which forced them to cycle and expand. 
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Figure 50: Pharmacological inhibition of S6K1 activity results in increased 
HSC frequency in human CD34+ cells.  
(A) Representative flow plot of UCB CD34+ cells following treatment with PF-
4708671. UCB CD34+ cells were treated with either vehicle or 5 µM of PF-
4708671 for 5 days and frequency of CD34+ CD38- cells was determined by 
FACS. (B) Quantitative representation of CD34+ CD38- cells in UCB CD34+ cells 
in presence or absence of PF-4708671 for 5 days. Experiment was performed in 
triplicates. Data are expressed as mean ± SEM; *p<0.05. 
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Previous studies have shown that increased cycling of HSCs contribute to 
functional defects (Jetmore et al., 2002; Srour and Jordan, 2002). To determine 
the effect of S6K1 inhibition on HSCs, NSG mice could be transplanted with UCB 
CD34+ cells following treatment with S6K1 inhibitor. If S6K1 inhibition increases 
engraftment of ex vivo cultured HSCs that would suggest S6K1 inhibition might 
be a potential therapeutic tool for areas such as gene transduction that requires 
preservation of HSC function while being cultured ex vivo and enhancing donor 
HSC function. Furthermore, inhibition of S6K1 in human HSC could be used as a 
tool to enhance efficiency of bone marrow transplantation if it increases 
expansion of functional HSCs. In bone marrow transplantation, total body 
irradiation (TBI) has been used as a conditioning regimen. However, TBI causes 
radiation-induced injury, which is partly mediated by generation of ROS within the 
cells (Bianco et al., 1991; Holler et al., 1990; Riley, 1994). Previously, it has been 
showed that mTORC1 is a positive regulator of ROS production in HSCs (Chen 
et al., 2008). In this study, we have shown that inhibition of S6K1 results in 
reduced mTORC1 activity. Based on this, administration of PF-4708671 could be 
explored as a probable therapeutic tool to mitigate cellular damages following 
TBI. 
Moreover, as inhibition of S6K1 results in increased HSC-enriched 
population in human UCB cells, it could be explored as a probable therapeutic 
target to enhance radiomitigation. Following a radiation accident, especially 
involving a significantly large number of affected individuals, hematopoietic 
transplantation might not be the practical approach given the logistics and timing 
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required. A more practical and ideal approach would be administration of drugs 
targeting molecules, inhibition of which will enhance HSC function in vivo. Further 
studies are required to determine the effects of PF-4708671 on physiological 
systems. If PF-4708671 does not has any adverse effect on physiological 
systems, and can enhance hematopoietic recovery and survival following 
exposure to irradiation, it can be considered for use as a potential radiomitigation 
agent. 
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